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ABSTRACT 
 
Rhodococcus equi causes pneumonia and extrapulmonary disorders in foals and other 
immunocompromised animals including people.  Although exposure to virulent R. equi 
is widespread in the environment of foals, only a small proportion of foals develop R. 
equi pneumonia at affected farms.  It remains unclear why some foals develop disease 
while other exposed foals do not.  Anecdotal evidence suggests there may be an 
underlying genetic predisposition to disease resulting from R. equi infection and the 
genetic contributions of the host remain ill-defined.   
 
A genome wide association study (GWAS) examining single nucleotide polymorphisms 
(SNPs) and copy number variants (CNVs) to identify regions of the genome contributing 
to disease was performed.  Although no associations were made with CNVs, a set (viz., 
four) of SNPs were significantly associated with R. equi pneumonia.  The SNPs 
identified localized to a region on chromosome 26 containing a potential candidate gene.  
The transient receptor potential cation channel, subfamily M, group 2 (TRPM2) gene is 
known to play a critical role in neutrophil recruitment and the severity of tissue damage 
at sites of inflammation.  One associated SNPs in the GWAS is located within this gene 
and was used, via PCR, to validate the GWAS finding in a joint analysis.  Joint analysis 
revealed a 3- to 4-fold increase in odds of disease for individuals homozygous for the 
SNP identified in TRPM2.  This finding was consistent across each clinical group 
compared. 
 iii 
 
RNA-Seq was performed to further investigate this region, as well as identify others 
across the genome, and understand the functional implications on gene expression that 
may be marked by the identified SNPs.  Each TRPM2 genotype was represented (viz., 
AA, AB, BB) in the 12 horses that were donors for sequencing.  RNA-Seq analyses 
identified several novel transcripts across the TRPM2 region; however, none were 
differentially expressed in relation to the TRPM2 genotypes.  Several genes identified as 
being differentially expressed were linked through pathway analysis which further 
implicated innate immunity as being a critical player in the pathogenesis of R. equi 
pneumonia.  Further studies are required to identify targets and practices for the control 
and prevention of R. equi pneumonia in foals.   
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CHAPTER I  
INTRODUCTION: GENETIC SUSCEPTIBILITY TO RHODOCOCCUS EQUI* 
 
Introduction 
Rhodococcus equi pneumonia is an important disease of foals most commonly 
characterized by chronic progression associated with development of large pulmonary 
abscesses 1.  Treatment of R. equi pneumonia is prolonged and expensive, and 
prevention is limited because transfusion of hyperimmune plasma is incompletely 
effective 2, chemoprophylaxis is inconsistently effective 3,4 and may promote 
antimicrobial resistance 5, and no effective vaccine is currently available 6.  Isolates of R. 
equi that are virulent in foals express the virulence-associated protein A (VapA), which 
is encoded by a gene, located within a pathogenicity island, on an approximately 85- to 
90-kilobase (kb) plasmid.  Expression of VapA alone however is not sufficient to cause 
disease 7,8.  Many different strains of virulent (and avirulent) R. equi have been shown to 
be present in a common environment (i.e., the same farm), and multiple genotypic 
virulent strains may exist even in an individual foal with R. equi pneumonia 5,9-11.  
Although exposure to R. equi is widespread at farms where foals are affected, only a 
variable proportion of foals will develop clinical disease at a given farm whereas other 
foals at the same location will not develop disease 12,13.  In addition, anecdotal reports by  
*Reprinted with permission from “Genetic Susceptibility to Rhodococcus equi” by McQueen et al., 2015. 
JVIM, doi: 10.1111/jvim.13616, 2015 by CM McQueen. 
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veterinarians indicate that some mares recurrently have affected foals whereas 
other mares from the same environment consistently have foals that do not develop  
R. equi pneumonia.  Taken together, these findings support the possibility of an 
important role for a genetic predisposition (i.e., susceptibility, resistance, or tolerance) to 
development of R. equi pneumonia and have prompted investigations of the genetic basis 
for this disease.  Pneumonia caused by R. equi is a complex trait.  Thus, it is unlikely 
that it will have a monogenic basis.  Nevertheless, studying the genetic basis of R. equi 
pneumonia is important because it could reveal information about crucial biological 
processes and pathways that influence the outcome of infection in foals, and identifying 
these pathways and processes might consequently lead to novel approaches for 
diagnostic testing, treatment, control and prevention. The purpose of this report is to 
review what is known about genetic predisposition to pneumonia caused by R. equi in 
foals and describe genetic techniques currently available to study the genetic 
determinants of development of R. equi pneumonia or other diseases in horses.  We 
begin by summarizing the current literature regarding genetic associations with R. equi 
pneumonia, and then discuss some more advanced genetic tools available for future 
studies to further investigate the genetic basis of R. equi pneumonia.    
 
Literature search  
A literature search was conducted to identify English language studies from any year 
that focused on foals, R. equi, and genetics.  Databases were searched in April 2014 
through Ovid including CAB Abstracts, MEDLINE, Embase, and BIOSIS. Search words 
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included (foals or equus or equine) and (r equi or Rhodococcus equi*) and gene*, where 
the asterisk indicates truncation.  Within each database, appropriate subject headings or 
index terms also were added.  A total of 744 articles were retrieved and de-duplicated, 
with 5 articles selected for inclusion.  This search was updated in September 2014. 
 
Candidate genes 
We identified 5 studies that attempted to identify genes associated with R. equi 
pneumonia. Four of these 5 studies have utilized a candidate gene approach (Table 1.1).  
The candidate gene approach involves either use of prior knowledge pertaining to known 
gene functions that might predispose to the disease of interest (e.g., the interferon-
gamma pathway and R. equi pneumonia) 14,15 or use of genes implicated in other but 
similar diseases that could be potential candidates for involvement(e.g., genes important 
for Mycobacterium tuberculosis which, like R. equi, is a gram-positive, facultative 
intracellular organism that replicates primarily within macrophages and causes 
pneumonia and could be potential candidates for R. equi pneumonia) 16-18.  To the 
authors’ knowledge, the first candidate gene association study of R. equi pneumonia 
compared the frequencies of single nucleotide polymorphisms (SNPs) in the transferrin 
gene (Tf) among Thoroughbred foals from Kentucky that died of R. equi pneumonia 
with those of control Thoroughbred mares 19.  In one study, the Tf gene was selected on 
the basis of its product’s ability to bind iron because iron sequestration is a known  
 4 
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host defense mechanism against bacterial replication 20,21.  The authors postulated  
that polymorphisms in the Tf gene might result in enhanced (or decreased) iron binding, 
which then could confer a selective advantage (or disadvantage) to survive infections 
with bacteria such as R. equi 19.  The authors used SNP frequencies to infer Tf alleles 
present within the study population, and allele frequencies were subsequently compared 
between the case and control groups.  The authors documented a significant (P < 0.05) 
abundance of the Tf F allele and a deficiency of the D1 allele among the cases (diseased 
foals) when compared with controls.  Limitations of this study included the fac
that sample size was relatively small, it was restricted to a single breed, a separate 
population for validation was not included, and no mechanistic studies (i.e., 
documentation that the F allele was associated with decreased iron-binding) were 
incorporated or cited. Nonetheless, a significant association of SNPs in the Tf gene with 
R. equi pneumonia was demonstrated, and this finding represented an important advance 
in knowledge.   
 
A later study seeking to identify a genetic predisposition to R. equi pneumonia utilized 
the candidate gene approach by comparing frequencies of 22 genetic markers among 51 
Thoroughbred foals from the Czech Republic 22.  These markers were either SNPs or 
polymorphic microsatellites in or near immune-related genes that had been previously 
identified (except for 5 markers that were first identified in this study).  No genetic 
variants were significantly associated with R. equi pneumonia, but some genetic variants 
were significantly associated with a higher burden of R. equi in tracheobronchial aspirate 
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(TBA) fluid from foals.  Specifically, loci on chromosome 10 and 15 were associated 
with R. equi infection when comparing the subset of foals with extreme phenotypes (i.e., 
foals with the highest numbers of R. equi in TBA fluid) to those with no R. equi.  The 
strongest association with TBA fluid phenotype was for the microsatellite HMS01 
located on chromosome 15 which encodes the genes for interleukin (IL)-1β (IL1β) and 
the IL-1 receptor antagonist (IL1RN).    Although the associations were relatively weak 
and the phenotype was for burden of R. equi in TBA fluid (rather than for pneumonia 
caused by R. equi), these results offer further evidence of a genetic basis for host 
response to infection with R. equi.   
 
A third study from our laboratory utilized previous findings indicating association 
between the solute carrier family 11 member 1 gene (SLC11A1) and susceptibility to 
intracellular bacterial infections in other species of animals 23-26.  The SLC11A1 gene 
encodes a protein relevant to innate immune responses to intracellular bacteria 27,28.  
Direct sequencing of the beginning of the gene transcript (i.e., the 5´ end of the gene) 
was used to identify SNPs that were compared between cases of R. equi and unaffected 
foals (controls) among Arabian horses at 2 farms (1 farm in Texas and 1 farm in 
Arizona). A novel SNP, -57T, in the 5´ untranslated region (UTR) was significantly 
associated with R. equi pneumonia 29.  The authors further screened for this 
polymorphism in 5 domestic horse breeds, donkeys, and zebras, and found it was 
represented in 4 of the 5 horse breeds. The observation that this SNP was represented 
across multiple breeds strengthened the study’s findings because if a marker were 
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present in only 1 breed, it would be possible (if not probable) that the identified marker 
was more likely associated with breed differences than disease.  Limitations of this study 
included the fact that association between the candidate gene and disease was only 
assessed within a single breed at 2 farms, and no validation of the association in another 
population was conducted.  Additionally, inconsistencies in diagnostic practices for R. 
equi pneumonia among farms in the study existed, which might have impacted the 
results 29. 
 
A fourth candidate gene study investigated the frequency of SNPs in selected immune 
response genes from DNA samples collected from 31 Thoroughbred foals from the 
Czech Republic  30 that had been used in a previous candidate gene study (described 
above) 22.  The candidate markers were used to asses allele frequencies between groups 
of foals classified on the basis of a binary outcome using a cut-point of > 5,000 colony 
forming units (CFU)/mL of vapA-positive R. equi in TBA fluid.  Twenty-five foals were 
categorized as below the cut-point because they had no bacteria cultured from them, and 
6 were categorized as above the cut-point 30.  An association was identified between a 
SNP in the IL-7 receptor (IL7R) gene and the presence of > 5,000 CFU of R. equi in 
TBA fluid.   Limitations of this study included lack of a validation population in which 
the association could be replicated, and, similar to the earlier study using these foals, the 
association was not made between the marker and disease but rather between the marker 
and the concentrations of bacteria present in TBA fluid. Regardless of these limitations, 
this study was scientifically important in that it implicated the IL7R gene in particular, 
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and innate immunity in general, as having a role in host response to infection with R. 
equi.   
 
The candidate gene approach is a valid method for genetic investigation and yielded 
positive associations in the aforementioned studies, strengthening the plausibility of a 
genetic contribution to susceptibility or resistance to R. equi pneumonia in foals.  
Moreover, the commonality of identifying innate immune responses as playing a role in 
host defense against infection with R. equi in these various candidate gene association 
studies is important to our understanding of the pathogenesis of R. equi pneumonia.   
 
Despite these positive results, the candidate gene approach has important limitations for 
making genetic associations.  Bias is introduced into the study design by selecting a 
small number of genes for evaluation, on the basis of either function of the gene 
product(s) or prior association of the gene with disease. This selection process 
effectively eliminates the ability of the investigators to examine both the enormous 
amount of genetic information in the remainder of the genome or the relationship and 
interaction of other genes with the genes of interest 17.  Other genetic elements present in 
the genome (e.g., sites critical to gene regulation) are missed by restricting analysis to 
candidate genes, because in most cases probes used to detect variation are not near each 
other and offer no information about neighboring genetic variation.  Assessing variation 
across the genome circumvents these limitations of the candidate gene approach.  
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Genome-wide studies in horses are now feasible because of recent technological 
developments. 
 
Genome-wide association studies  
Genome-wide association studies (GWASs) rapidly gained popularity after the 
sequencing of the genomes of several animal species, including human beings 31-34.  The 
completion of the sequencing and assembly of these reference genomes (an assembly of 
the DNA sequence and its chromosomal locations representing the genetic baseline of a 
species) provided a tool that could be used as a map indicating where elements of the 
genome reside.  Substantial efforts then were made to catalogue the locations of genes 
and genetic variation identified within these species 35,36.  Single nucleotide 
polymorphisms proved useful for characterizing genetic variation among individuals of a 
given species, and the development of SNP array technology made it possible to perform 
> 1 million association tests simultaneously of markers across the entire genome without 
the expense or labor of genome sequencing.  
 
Single nucleotide polymorphism arrays are glass slides with genomic probes (sequences 
of DNA) that capture SNPs present within a given species. Through a hybridization 
process, the probes bind DNA of samples to identify which polymorphisms are present 
in that sample 37.  These SNP arrays enabled clinical researchers to compare clinically 
affected horses with unaffected controls so as to examine the association of various 
health disorders with markers on a genome-wide basis, and the interplay among different 
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genetic variants associated with disease 38.  Results from a GWAS are readily 
identifiable because they typically are visualized by plotting the negative logarithm of 
the P value for the association of a given SNP with the outcome of interest as the 
ordinate (vertical axis) and the chromosome number as the abscissa (horizontal axis).  
The resultant scatter plots are known as Manhattan plots because they resemble the 
skyline of a major city with some points that tower over the majority of others.  
Determining the genome sequence of the domestic horse led to the development of 2 
equine SNP arrays that could be used for GWAS by researchers 32,39.  
 
 Currently, a single SNP array has been developed, well characterized, made 
commercially available, and utilized in numerous GWAS in horses.  For example, the 
EquineSNP70 BeadChip Arraya contains approximately 74,000 SNPs positioned across 
the equine genome that can be simultaneously tested to identify their associations with a 
phenotype of interest 39,40.  Recently, a higher density SNP array with approximately 
770,000 SNPs across the equine genome has been developed but has not been 
characterized in peer-reviewed literature to date.  Several GWAS in horses using SNP 
arrays and yielding positive associations have been reported 41-46.  Genome-wide 
association studies rely on observing different frequencies of alleles (identified by SNPs) 
that segregate with a phenotype of interest.  These associations have identified regions of 
interest (Figure 1.1 A), which are further investigated to understand what elements  
  a EquineSNP70 BeadChip ArrayIllumina, San Diego, California, USA 
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Figure 1.1.  Association studies, CNVs, and SNPs.  (A) The colored blocks indicate 
different alleles or haplotypes present in the horse genome. These have been identified 
by either a CNV or a SNP but any type of genetic variation can be used to identify 
alleles.  The boxed regions show a greater frequency of the orange allele in the cases 
compared to the controls.  The increased frequency of this allele in the cases suggests 
that it may harbor a variant(s) causing or contributing to the associated phenotype.  (B) 
CNV – A represents a single copy of a gene; CNV – B represents a duplication of the 
gene; and, CNV – C represents a deletion of the gene.  These examples demonstrate how 
CNVs can affect a single gene and can be used to identify different alleles in a 
population.  SNPs, represented as red bases, offer the ability to identify alleles because 
of their polymorphic nature. Either type of genetic variation can be used in a GWAS to 
identify disease associated alleles. 
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(e.g., genes, promoters, other variants), pathways or processes are associated with the 
phenotype.   
 
The reason marker associations require region investigation is because of linkage 
disequilibrium (LD), which is defined as the non-random association of genetic 
information 47.  Linkage disequilibrium is a phenomenon that allows for the prediction of 
the non-genotyped genetic information around a genotyped marker because of an 
assumption that the genetic material around a marker differs and thus can be based on 
the allele represented by the marker (i.e., SNP).  The use of LD to make disease 
associations leverages inheritance patterns, selection, and evolution and is a fundamental 
concept underlying GWAS.  The association of a marker, whether it is located in a gene 
or in a noncoding region of the genome, should only be treated as an indicator of the 
need to further investigate the area.  An association of a SNP with disease neither 
indicates that the SNP is causally associated with the disease nor that the specific gene in 
which the SNP lies is the gene of interest.  A SNP only indicates that there might be 
genetic variation in the area of the genome where the SNP is located.  The size of the 
area of interest is largely described by the length of the LD (i.e., the number of bases for 
which another gene or genetic element can be expected to be in LD with the marker).  
Using LD to assist in making associations is a powerful tool that is genome-wide and 
efficient because not all markers across a genome must be tested to find an associated 
region, should one exist.  The power of LD allows fewer markers to be present on an 
array, and hence decreases the number of necessary test corrections.  Furthermore, the 
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longer the LD of the species, the fewer SNPs are necessary to identify significant 
associations.  Estimates of LD for breeds of horses are markedly longer than those for 
humans 48,49.  Thus, one might expect to need fewer SNPs on an equine array to have the 
same discriminatory power as a human array or to have greater power in a GWAS for 
horses than humans for an array of the same size or density of SNPs. 
 
Although SNP arrays are proving to be a powerful tool for investigating the relationship 
of genetic and phenotypic variation, challenges exist with validating and reproducing 
results generated by SNP-based GWAS.  There are likely many contributing risk alleles 
for all complex traits and complex diseases such that no single allele can explain all of 
the phenotypic variation 50.  This becomes problematic during replication using different 
breeds and populations because the markers identified might merely reflect breed 
differences, or the markers might represent different alleles conferring different levels of 
risk across breeds or populations.  The number of association studies in equine genetics 
will only continue to increase and the equine research community will continue to face 
these challenges.  Appropriate study designs, accurately defined and categorized 
phenotypes, and functional follow-up assays will be essential to maximize the utility of 
GWAS results in future studies 51.     
 
The first report of a GWAS with R. equi pneumonia recently was published by our 
laboratory 52.  The study 53 population included 248 foals born in 2011 at a large Quarter 
Horse breeding farm.  For a separate study characterizing the accuracy of screening tests 
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for R. equi pneumonia, foals at the farm were examined by thoracic ultrasonography 
every 2 weeks beginning at 3 weeks of age and continuing through 19 weeks of age (or 
until weaned) to identify foals with areas of pulmonary consolidation or abscess 
formation attributed to R. equi infection.  Farm personnel were blinded to the 
ultrasonographic findings and a separate team of individuals performed thoracic 
ultrasonography.  Foals at the farm were classified as having R. equi pneumonia (N = 43; 
on the basis of clinical signs of pneumonia, isolation of virulent R. equi from the TBA 
fluid, cytologic evidence of sepsis in TBA fluid, and ultrasonographic evidence of 
pulmonary consolidation or abscess formation > 1 cm in maximal diameter), no 
pneumonia (N = 49; on the basis of absence of clinical signs of pneumonia and no 
ultrasonographic evidence of pulmonary consolidation or abscess formation > 1 cm 
diameter), and subclinical pneumonia (N = 156; on the basis of absence of clinical signs 
of pneumonia with ultrasonographic evidence of pulmonary consolidation or abscess 
formation > 1 cm diameter).    From each of these 3 subpopulations of foals, a sample of 
24 foals was randomly selected for genotyping using the EquineSNP70 BeadChip Array.  
Comparisons among the 3 groups identified a significant association of a region on 
chromosome 26 that included the gene for the transient receptor potential cation channel, 
subfamily M, member 2 (TRPM2).   
 
These results are notable because the TRPM2 gene is known to play a role in neutrophil 
function and recruitment.  In a study using TRPM2 knock-out mice and a model of 
ulcerative colitis, TRPM2-deficient mice had less tissue damage at sites of inflammation 
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than did wild-type mice 54.  The association of the TRPM2 was validated using 
polymerase chain reaction (PCR)-based genotyping of the locus in the remaining 176 
study foals that were not tested using the SNP array.  The principal limitations of this 
study were that only a single breed at a single farm was studied, and that no association 
of the genotype with function of the TRPM2 gene-product or associated signaling 
pathways was identified.   Nonetheless, this study is interesting in that, consistent with 
previous candidate gene studies, a gene related to innate immunity was associated with 
R. equi pneumonia, and the study provides further evidence of the underlying genetic 
basis for R. equi pneumonia.     
 
Copy number variants 
Although the genetic determinants of phenotypic variation are largely dependent on the 
gene or genes and the manner in which they exert their effect (e.g., altering the 
biochemical properties of a protein, changing the expression patterns or levels of 
messenger RNA), recent studies have implicated copy number variants (CNVs) as major 
determinants of phenotypic variation in humans and animals 55-57.  As the name implies, 
CNVs are characterized by changes in the number of copies of DNA between at least 2 
individuals (Figure 1.1 B) 58.  Their sizes can range from hundreds to millions of base-
pairs (bps).  Although they often are enriched in certain regions of the genome that 
predispose to their formation, CNVs have been detected throughout the genome, with 
many CNVs involving multiple genes, individual genes, or components of a single gene.  
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Several mechanisms have been shown to cause the formation of CNVs.   During meiosis 
in the germ cells, homologous chromosomes align with each other to exchange genetic 
information between the parental genomes.  This process, called homologous 
recombination or crossing over, plays an instrumental role in expanding the genetic 
diversity of a population.  In rare instances however, the exchange of genetic material 
can occur between 2 different sites (non-allelic homologous recombination [NAHR]), 
resulting in an unequal exchange of genetic material 59.  Although NAHR often is the 
source of many disease-causing CNVs, this process plays a key role in the formation of 
gene families and the birth of new genes.   Naturally-occurring DNA repair mechanisms 
also can delete or duplicate DNA.  For example, the non-homologous end joining 
(NHEJ) and microhomology mediated end-joining (MMEJ) pathways are used to repair 
double-stranded DNA breaks that occur in the genome.  During the repair of the breaks, 
the NHEJ and MMEJ pathways either add or remove DNA to ligate the broken strands 
back together 60-62.  Fork stalling and template switching (FoSTeS) is a mechanism used 
to circumvent a stalled replication complex during DNA synthesis.  When this happens, 
the FoSTeS machinery identifies a similar sequence at a nearby replication site to re-
engage the stalled complex, leading either to a deletion or duplication of the 
circumvented segment of DNA 63.  Microhomology-mediated break-induced repair is 
another mechanism believed to give rise to CNVs under stressed cellular conditions in 
which traditional break-induced repair does not occur and therefore homologous 
sequences are identified to continue replication 57,64.  Overall, there are numerous 
pathways and processes that can lead to the formation of a CNV.  
 17 
 
Identification of CNVs across the genome has proven to be challenging because of the 
dependency on probe density to increase resolution and the physical limitation of the 
number of probes that can be placed on a single array.  Array design technology 
continues to advance and undoubtedly will increase our ability to identify CNVs by 
enhancing genome resolution via probe density.  Two studies in horses have used the 
EquineSNP70 BeadChip Array to search the equine genome for CNVs 65,66.  The use of 
the equine SNP array to identify CNVs highlights the usefulness of the SNP array, but, 
there are limitations when SNP arrays are used solely for the purpose of identifying 
CNVs.  The probes present on SNP arrays are often evenly distributed across the 
genome, thus spanning large distances and allowing only for the identification of large 
CNVs.  The SNP arrays also are not well suited for identifying CNVs in structurally 
complex regions (e.g., gene families, segmentally duplicated regions).  Probe design 
often is difficult in these regions, thus they are excluded from the array 67-69.   
 
 18 
 
 
Figure 1. 2.  Comparative genomic hybridization method to identify CNVs in horses.  
(A) Genomic DNA is isolated from subject horses (cases and controls) and a single 
reference horse.  (B) Genomic DNA from the subject horses are independently labeled 
with a red dye and genomic DNA from a single reference horse is labeled with a green 
dye.  (C) Labeled DNA from a single subject horse and the reference horse are mixed 
together at equal ratios and competitively hybridized onto a comparative genomic 
hybridization array.  (D) Fluorescent image of array after hybridization of subject and 
reference DNA. The spots on the array represent individual oligonucleotides.  Yellow 
spots reflect regions with equal DNA content, and red and green spots reflect unequal 
ratios of DNA between the subject and reference horse, respectively.  (E) Plot of 
normalized log2 ratios of oligonucleotides on the array.  The Y-axis represents 
normalized log2 ratios of fluorescent signals for each spot on the array.  The X-axis 
represents the relative genomic coordinates of each oligonucleotide.  For example, a log 
2 ratio < 1 and > -1 (black dots) indicates equal DNA content between the subject and 
reference horses.  A log2 ratio >1 and < -1 indicates unequal DNA content between the 
subject and reference horses.   
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Several studies have used technologies other than SNP arrays to identify CNVs in 
horses, such as next generation sequencing (NGS) and comparative genomic 
hybridization arrays (aCGH) 52,70-74.  Arrays for CGH are designed by tiling 
oligonucleotide probes across the genome to which DNA of interest then can be 
hybridized for identification of CNVs (Figure 1.2).  Use of aCGH also has limitations 
for identification of CNVs, principally related to probe placement and density.  The 
currently published equine arrays are a whole genome tiling array (i.e., probes tiled 
across the whole genome) and an exon tiling array (i.e., probes tiled across non-coding 
and  coding exons of genes) 71,72.  Thus, these arrays only permit evaluation of CNVs 
within specific regions of the genome.  The results of studies identifying CNVs by NGS 
are limited by variation in read-depth (i.e., the number of copies of sequences aligned to 
a specific area) across the genome and the size of the CNVs identified.  Specifically, 
CNVs of lengths ranging from 197 bp to 3.5 Mb have been identified and confirmed 
using a CGH array designed to identify CNVs in genes of the equine genome 71.  In a 
subsequent study using NGS, CNVs ranging in length from 3.74 kb to 4.84 Mb were 
identified 70.  There is, however, a trade-off when using either approach.  Targeted arrays 
can identify smaller CNVs, but they are only able to identify CNVs within regions 
targeted on the array.  Conversely, NGS can be used to identify CNVs throughout the 
entire genome, but NGS approaches to identifying CNVs are limited because of their 
bias towards larger CNV size.  Although there are discrepancies among the approaches 
used to identify CNVs, the studies to date have identified CNVs in genes involved in 
similar pathways, such as sensory perception, signal transduction, and immune related 
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pathways.  Results from some CNV studies of horses also have found concordant results 
between aCGH and NGS whole genome sequencing in which CNVs of horses have been 
shown to be enriched in genes relating to sensory perception, signal transduction, and 
immune related functions 71,72.   
 
Our laboratory conducted a CNV-based GWAS by applying the aforementioned equine 
exon tilling array 71 to the 72 foals studied in our SNP GWAS 52.  Although similar 
lengths and numbers of CNVs were observed in these foals as in the previous report 
using this array, no CNVs were significantly associated with R. equi pneumonia in these 
foals.  This finding does not preclude the possibility that CNVs contribute to 
susceptibility to R. equi pneumonia because only CNVs within exons were considered.  
The CNVs located within other elements such as promoters and silencers that were not 
detected by the array might influence the odds of foals developing R. equi pneumonia.  
Moreover, sample size was small, which might have limited our ability to detect 
anything less than very strong associations.  Future efforts should include the design and 
implementation of adequately powered studies using tiling arrays focused at gene 
promotors, gene expression enhancers, and other regulatory elements that are both near 
and within genes.  Much remains to be investigated to characterize CNVs in horses and 
to study the role of CNVs in susceptibility to R. equi foal pneumonia and other diseases 
of horses.  Because CNVs represent a change in genetic content (i.e., deletions and 
duplications), they may have the potential to greatly impact many phenotypes.  A 4.6-kb 
duplication in an intron has been associated with graying and melanomas in horses 75.  A 
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16.1-kb duplication has been shown to cause wrinkling of the skin in Shar-Pei dogs 76.  
In humans, CNVs are believed to play critical roles in neurodevelopmental disorders, 
psychiatric disorders, and cancers 77,78.  A number of studies have described CNVs in 
cattle.  Overall, the CNVs identified to date are enriched in genes related to immune 
function and sensory perception, which also has been observed in horses 79. 
 
Next generation sequencing techniques 
The invention of next generation sequencing (NGS) technologies has opened a new 
world of opportunities for understanding genetic variation and its role in disease 
pathogenesis.  The NGS technology has enabled rapid sequencing of the genomes of 
individuals at a low cost and with maximum genome coverage 40.  Before NGS, the gold 
standard for sequencing technology was automated Sanger sequencing 80.  Sanger 
sequencing technology was developed in the late 1970s and later automated to increase 
throughput 81.  Next generation sequencing technologies differ among companies, but 
they all share a principal advantage over Sanger sequencing in that they are capable of 
sequencing multiple DNA fragments (i.e., an entire genome) in a single sequencing 
reaction (versus sequencing small fragments piece-by-piece in multiple reactions) 82.  
The opportunities provided by NGS technology are accompanied by the challenge of 
managing and analyzing datasets of enormous size. The ability of NGS to generate data 
has out-paced the ability of scientists to interpret it.  Developments in bioinformatic and 
biostatistical software have facilitated our ability to visualize and make inferences from 
large datasets.   
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Both DNA and RNA can be sequenced using NGS methods. Sequencing the genome 
(DNA) and transcriptome (RNA) offers 2 interrelated but distinct biological approaches.  
Genome sequencing using NGS can characterize all of the variants known to exist in 
gene sequences, including single base changes (SNPs), insertions and deletions, CNVs, 
and genetic variation in non-genic regions.  The first application of NGS for genome 
sequencing in horses yielded the genome sequence of a Quarter Horse mare 70.  
  
Sequencing of the genome, however, does not reflect which elements of the DNA are 
transcribed.  Moreover, transcription generally should be considered at the level of a 
specific tissue or cell type because of inter-cellular variation in gene expression.  
Although the DNA sequence is common to all cells in an individual, the genes expressed 
vary among cells or organs of the same individual.  Sequencing RNA yields a snapshot 
of the expressed genes of the tissue or cell type that cannot be identified by DNA 
sequencing.  The process of sequencing RNA using NGS methods is termed RNA-Seq; 
it may be applied either to total RNA (all forms of RNA) or specific types of RNA.  
Most commonly, RNA-Seq is applied to messenger RNA (mRNA) to reflect which 
portions of the genome are being transcribed in the specimen.  Arriving at RNA-
sequencing is a multi-step process which first requires deciding from which tissue or 
body-fluid RNA should be extracted to best answer the biological questions being asked.  
Briefly, isolated RNA is converted to complementary DNA (cDNA) in order to construct 
a library that represents all of the RNA isolated and to be sequenced (Figure 1.3).  The 
representative libraries then are sequenced, generally in a paired-end fashion.  Paired-
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end sequencing reads are generated by sequencing from both ends of a cDNA fragment 
(i.e., from the 5’ end of both strands of the cDNA fragment).  Paired-end reads are 
extremely valuable because 2 complementary pieces of information have been generated 
about the same cDNA fragment, and this greatly increases the accuracy of mapping 
these RNA sequences back to their respective genes of the genome.  
 
RNA-Sequencing is an invaluable tool for gaining insight into biologically relevant 
questions such as differences in gene expression by different alleles and gene expression 
of a target specimen under different biological or biochemical conditions. Several 
downstream RNA-Seq   
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Figure 1.3.  RNA-Seq flowchart.  Isolated RNA is converted to cDNA, a stable 
molecule, which can then be amplified and sequenced.  Sequencing reads are then 
aligned to the genome assembly (sequence only) to identify their locations based on 
nucleotide matches.  Mapping the reads to a gene annotation list will generate the 
number of sequencing reads that have aligned with a particular gene and are called 
counts.  These counts at any particular gene are representative of the amount of gene 
expression in the sample and can be compared across horses to identify differentially 
expressed genes. 
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processing and analysis programs can be used to identify differentially expressed genes, 
novel transcripts, and multiple isoforms of gene transcripts in order to find answers to 
biological or clinical questions 83-85.  The conclusions inferred from these analyses can 
lead to identifying potential biological pathways and processes that can be targeted for 
development of novel interventions, including treatments and preventative measures.  
Several studies have reported the application of RNA-Seq in horses in attempt to identify 
differentially expressed genes 86-95.  To the authors’ knowledge, the first report of RNA-
Seq  in horses was an effort to characterize the transcriptome and tissue-specific 
expression profiles from 8 equine tissues 94.  A subsequent study focused on 
characterizing gene expression by RNA-Seq in immunologically active tissues 95.  
Investigators have used RNA-Seq to characterize the expression profile of genes critical 
to the differentiation and regulation of cells during embryogenesis 90,  and to 
characterize the expression and inferred function of RNAs in the equine sperm 
transcriptome 89.  Several studies also have used RNA-Seq in horses to identify 
differentially expressed genes when comparing blood, muscle (obtained by biopsy), or 
both before and after exercise or racing 86,87,92.  These studies have successfully 
identified pathways involved in stress during and while recovering from exercise.  
Others studies have sought to answer more specific question such as identifying 
expression differences in the cartilage of the metacarpophalangeal joints of young and 
old horses in an attempt to shed light on genes involved in the development and aging of 
cartilage 93.  Use of RNA-Seq of hoof lamellar basal epithelial cells has been performed 
to identify cell-signaling pathways indicative of the early stages of laminitis 91.  Using 
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RNA-Seq, an association has been demonstrated of a long terminal repeat (a genetic 
element inserted in the past by conversion of viral RNA to cDNA and subsequently 
incorporated in the genome of the host) with congenital stationary night blindness and 
leopard spotting in horses 88. 
 
Our laboratory currently is analyzing RNA-Seq data to identify differentially expressed 
genes of foals representing the 3 genotypes of the TRPM2 SNP identified in our SNP-
based GWAS to better understand the role of this (and possibly other) gene in 
susceptibility to R. equi pneumonia.  We also currently are applying RNA-Seq to 
leukocytes collected from healthy and R. equi-affected foals to gain insights about gene 
expression of these immune-related cells.  These studies will further our understanding 
of R. equi pathogenesis and, hopefully identify critical biological pathways and 
processes involved in disease development.   
 
The genetic basis of a common and complex disease such as R. equi pneumonia is likely 
polygenic.  Gene expression profiling by RNA-Seq thus will be an essential step in 
understanding the relationships and interactions of multiple genes with this disease.  The 
identification of genes that are up- or down-regulated after pathogen exposure can reveal 
host responses critical for defense against infection.  When evidence of differential gene 
expression is identified by RNA-Seq (or other methods), it then becomes necessary to 
understand the mechanistic cause driving the change in expression (i.e., variation within 
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regulatory elements, changes in epigenetic modifications, structural variation, post-
transcriptional and post-translational modifications).   
 
Conclusions 
Research findings regarding genetic relationships with disease continue to substantiate 
that most common and complex diseases are not monogenic.  This likely is true for R. 
equi pneumonia.  The evidence to date, as summarized in this review, indicates that 
susceptibility to R. equi pneumonia is not controlled by a single gene.  It is increasingly 
clear that both innate and adaptive immune responses as well as their interactions are 
critical for protecting foals against R. equi infection. Genetic association studies have 
specifically implicated innate immune responses, but innate immune responses are 
critical for orchestrating adaptive immune responses and it may be an over-
simplification to dichotomize these responses.  It is likely that there also are epigenetic 
factors involved in regulating gene transcription of critical immune-related genes, which 
adds further complexity to the pathogenesis of R. equi pneumonia in foals.  Future 
proteomic studies also will be required to follow-up on promising genetic findings as 
protein concentrations, structures, and interactions are critical to disease development 96.  
Proteomic studies may be able to answer critical questions such as protein 
concentrations in diseased and non-diseased foals and variable consequences related to 
protein concentrations and their interactions, which cannot be answered with molecular 
genetic techniques and sequencing.  With more genotypic-phenotypic associations being 
identified in horses, it will be challenging to investigate the causal implications of 
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genetic variants with functional assays.  Mechanistic studies (e.g., knock-out or knock-in 
genes) can be become very expensive and would not be feasible in horses.  Developing 
rodent models of important equine diseases and use of mechanistic studies in cell culture 
assay will be required to understand the functional consequences of identified 
associations with genetic markers.   Moreover, it will be important to remain mindful of 
the agent-related and environmental factors that contribute to disease development.  No 
single genetic tool or technique will identify the factors that render some foals 
susceptible to R. equi whereas others in the same environment remain clinically 
unaffected. The future will require a multifaceted approach to integration and analysis of 
data from multiple sources to successfully identify the critical pathways and processes.  
We believe that molecular genetic and epigenetic methods will play an important role in 
solving the complex riddle of susceptibility to R. equi pneumonia in foals.   
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CHAPTER II 
IDENTIFICATION OF GENOMIC LOCI ASSOCIATED WITH 
RHODOCOCCUS EQUI SUSCEPTIBILIY IN FOALS* 
 
Introduction  
Rhodococcus equi is an important intracellular pathogen affecting horses, most 
commonly among foals in which it causes chronic, suppurative bronchopneumonia 29, as 
well as extrapulmonary disorders 97.  The cumulative incidence of pneumonia caused by 
R. equi may be high at breeding farms with affected foals, and this disease may 
adversely impact future racing performance 98.  At affected farms, a varying proportion 
of foals will develop clinical signs of pneumonia while the other foals remain free of the 
disease; however, subclinical pneumonia can occur following either experimental or 
natural infection with R. equi 99-101.   
 
Although the factors contributing to R. equi pneumonia are complex, recent evidence 
suggests that some horses may be genetically predisposed to this condition 19,29,30.  
Identifying the genetic and biological basis of susceptibility, or perhaps resistance, to R. 
equi pneumonia in foals is important, because it might lead to the development of 
diagnostic and therapeutic tools to manage at-risk foals on breeding farms and might 
shed light on critical host defense mechanisms.  Currently, single nucleotide 
*Reprinted with permission from “Identification of Genomic Loci Associated With Rhododococcus Equi 
Susceptibility in Foals” by McQueen et al., 2014. PLos ONE, 9:e98710, 2014 by CM McQueen. 
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polymorphism (SNP)-based genotyping platforms are available for performing genome-
wide association studies (GWAS) in horses 102.  Use of  SNP-based genotyping 
platforms to identify genomic regions associated with particular phenotypes in animals is 
growing at a rapid pace 45,46,102-105.  As a result, researchers, veterinarians, and producers 
increasingly rely on data from these studies to make important production and 
management decisions 106,107.  
 
Although high-density SNP arrays are powerful tools for performing association studies, 
they are often inadequate for examining structurally complex regions, particularly those 
enriched with copy number variants (CNVs) 67.  Results from the 1000 Genomes project 
estimate approximately 20% of CNVs are not in linkage disequilibrium with flanking or 
tagging SNPs 68, indicating that additional testing is required to accurately genotype 
these variants.  The identification of CNVs is further complicated by the probe 
placement and design of most commercial SNP arrays 67-69. Comparative genomic 
hybridization (CGH) arrays are optimized for genotyping CNVs.  Using SNP and CGH 
arrays together may, in some instances, increase the power of a GWAS by expanding the 
number of informative markers, particularly within structurally complex regions of the 
genome 69. 
 
In horses, CNVs are present in genes involved in many biological processes and may 
underlie or modify many common and disease traits 65,66,70.  Of the CNVs in horses 
identified to date, most are enriched in genes involved in sensory perception, signal 
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transduction, and metabolism 70.  In other animal species, including horses, CNVs often 
affect genes regulating the immune system, particularly the MHC; they may also be 
causative or modifying variants of many immune related conditions 108-115.  
 
The genetic basis of susceptibility or resistance to R. equi pneumonia has not been 
explored on a genome-wide basis.  Here, we describe independent SNP- and CNV-based 
GWAS to identify genomic loci associated with R. equi pneumonia in Quarter Horse 
foals. We identified a number of regions associated with R. equi pneumonia, including a 
region on chromosome 26.  Located within this region is the transient receptor potential 
cation channel, subfamily M, member 2 (TRPM2) gene that encodes a protein associated 
with neutrophil function.   
 
Materials and methods 
Ethics statement 
All protocols for this study were reviewed and approved by the Clinical Research 
Review Committee (CRRC Protocol 10-12), College of Veterinary Medicine & 
Biomedical Sciences, Texas A&M University.  This study was carried out on private 
land (33°37′14″N 100°19′22″W) and specific permissions for use were granted by GPB.  
During the time this study was conducted, research involving client-owned animals at 
Texas A&M University was not subject to review by the Institutional Animal Care and 
Use Committee.  Written informed consent for participation was obtained for all foals 
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included in the study, and the 6666 Ranch provided access to the foals included in this 
project. This study did not involve any endangered or protected species.  
  
Study population 
The 6666 Ranch was selected as the site for this study because it agreed to provide 
access to foals, had history of R. equi pneumonia among foals with a cumulative 
incidence of > 15% for the preceding 3 years, and because the farm’s veterinarian/ 
general manager (GPB) was conducting a separate study during 2011 evaluating 
screening tests for R. equi pneumonia in foals, which was directed by one of the authors 
(MKC).  The screening test evaluation required that treatment was not initiated for any 
foal on the basis of screening test results alone, and that the veterinarians making 
decisions about diagnosis and treatment of R. equi pneumonia were not informed of the 
results of screening tests.  Each foal at the farm underwent bilateral thoracic 
ultrasonographic examination at 2-week intervals, beginning at 3 weeks of age either 
until 19 weeks of age or until the foal developed clinical signs of pneumonia (as 
described below).  Ultrasonographic examinations were performed by a veterinarian who 
did not participate in diagnosis or treatment of R. equi pneumonia. The anatomic 
location (left versus right hemithorax; intercostal space; and, dorsal, middle, or ventral 
region) and maximal diameter of any areas of pulmonary abscesses or consolidation 
were recorded. In addition, the total number of lesions was counted.   
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All foals [N = 248] born at the farm during 2011 were eligible to be included in the 
study.  All foals were monitored daily by farm personnel for clinical signs of pneumonia 
until 20 weeks of age. Clinical signs suggestive of pneumonia included fever, lethargy, 
signs of depressed attitude, cough, nasal discharge, polysynovitis, tachypnea, increased 
respiratory effort, respiratory distress, and detection of a tracheal rattle or pulmonary 
crackles or wheezes via thoracic auscultation.  For each foal that developed clinical signs 
of pneumonia, thoracic ultrasonography and collection of a trans-endoscopic 
tracheobronchial aspirate (TBA) sample with a commercially available triple-guarded 
catheter (Triple stage tracheal wash catheter, MILA International Inc., Erlanger, KY) 
were performed. Between uses, the endoscope was disinfected with a 3.4% 
glutaraldehyde solution (CIDEX-PLUS, Advanced Sterilization Products, Irvine, CA) 
following a standard protocol used in our laboratory and known to be microbicidal 
against R. equi. Each sample of TBA fluid was submitted for microbiologic culture and 
cytologic evaluation to the Texas Veterinary Medical Diagnostic Laboratory in College 
Station, Texas.     
 
Foals with R. equi pneumonia (clinical group; N = 43 [17%]) were defined as those 
having signs of pneumonia at 3 to 20 weeks of age, ultrasonographic evidence of 
peripheral pulmonary consolidation or abscesses at the time of examination for clinical 
signs of pneumonia, and R. equi detected in TBA fluid via microbiologic culture, and 
cytological evidence of gram-positive intracellular coccobacilli in the TBA sample.  
Subclinical foals (N = 156 [63%]) were defined as those having ultrasonographic 
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evidence of peripheral pulmonary consolidation or abscesses, but lacking clinical signs 
of pneumonia 116.  Unaffected foals (N = 49 [20%]) were classified as having no clinical 
signs of pneumonia and no ultrasonographic evidence of pulmonary consolidation or 
abscessation. From each of the 3 groups of foals (i.e., clinical, subclinical, and 
unaffected), 24 foals were selected randomly for the SNP- and CNV-based genome-wide 
association studies. The rationale for including 24 foals was based on funding available 
to conduct the study (rather than an a priori sample size calculation). 
 
DNA samples and isolation 
A blood sample (4 mL) was collected by jugular venipuncture into a tube containing 
acid citrate dextrose (ACD) as an anticoagulant from the first (i.e., age 3 weeks) blood 
sample obtained from each foal.  Genomic DNA was isolated using a standard phenol-
chloroform isoamyl extraction protocol from these blood samples from each foal 70.  
 
SNP genotyping and data analysis 
The SNP genotyping was performed at Gene Seek (Neogen, Lincoln, NE) using the 
EquineSNP70 BeadChip Array (Illumina, San Diego, CA).  The resulting SNP 
genotypes were analyzed using the PLINK analysis package 117. Genotypes were 
determined for each animal and then filtered (i.e., excluded) on the basis of missingness 
per individual (> 10%), missingness per SNP (> 10%) minor allele frequency (< 5%), 
and absence of Hardy-Weinberg equilibrium (P< 0.001), as described by 
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 Raudsepp et al. 45.  A standard chi-square association test (Max(T) permutations [N = 
10,000]) based on a binary outcome of disease status using a case-control design was 
performed using PLINK 44,45. Genotype ped files were loaded into PLINK and foals 
were assigned a phenotypic status of either affected or unaffected (case/control).  A P 
value of P < 1 x 10-5  was considered evidence of association 118.  Population 
stratification was determined using plots of the observed versus the expected -log10 P 
values of Cochran-Armitage trend tests and by determining the genomic inflation factor, 
λ, using the R package GenABEL 119.  Using the R package pedigreemm 120, mixed-
effects logistic regression with sire modeled as a random effect was used for the 
association test in comparisons showing evidence of population stratification; SNPs with 
any genotype represented fewer than 10 times were removed from analysis to permit 
model convergence 119-121.  All SNP array data have been deposited in NCBI's Gene 
Expression Omnibus (GEO) 122 and are accessible through GEO Series accession 
number GSE57510 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57510).  
 
Joint analysis  
Genotyping for the joint analysis was performed using a tetra-primer AMRS PCR 
genotyping reaction 123 of an individual SNP (SNP ID:UKUL3936) present on the 
EquineSNP70 array and located within the TRPM2 gene (Forward outer: 5`-
ATCAGCCAGACACTCCAGGCATGACAT-3`; Forward inner: 5`-
CATCCTCCTCAGCCACCTGCATCTTTT-3`; Reverse outer: 5`-
ATCTCAGAAGGAGCTGCCATGCCTACC-3`; and, Reverse inner: 5`-
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GTATCTTCAGGACCACCCTCCTGACGC-3`).  The primers were designed using 
Primer3 software 124 and synthesized by Sigma-Aldrich (St. Louis, MO).  The PCR 
reactions were performed under these conditions: 9.8 µl mili-Q H20, 4 µl Taq 
FlexiBuffer (Promega, Madison, WI), 2 µl MgCl2, 0.4 µl dNTPs, 0.1 µl Taq (Promega), 
1 µl forward and reverse inner primer, 0.1 µl forward and reverse outer primer, and 1.5 
µl of DNA at 50 µg/µl.  Cycling conditions were as follows: 94°C for 2 m; 35 cycles at 
94°C for 1 m; 65.8°C for 1 m; 72°C for 1 m; and, a final extension at 72°C for 2 m.  
PCR amplicons were resolved on a 2% agarose gel.   
 
Genotype data from the joint analysis were analyzed using logistic regression on the 
basis of the binary outcome of disease (pneumonia versus each of the respective 
comparison groups [i.e., clinical foals, subclinical foals, and unaffected foals]).  The 
association of disease with genotype for the SNP was expressed as the odds ratio (OR), 
estimated from logistic regression modeling; 95% confidence intervals were estimated 
using maximum likelihood methods.  Models were fit for comparisons of clinical versus 
subclinical foals, clinical versus the combination of subclinical and unaffected foals, and 
clinical versus unaffected foals. Models were fit using S-PLUS statistical software 
(Version 8.2, TIBCO, Inc., Seattle, WA).  A significance level of P < 0.05 was used for 
the analyses. 
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CNV detection and analyses 
Copy number variants were identified using a previously reported equine exome array 
for comparative genomic hybridization (CGH)71. An individual Quarter Horse mare was 
used as the reference sample for each CGH experiment 70. Array CGH was performed 
using methods described by Doan et al. 71.  Briefly, genomic DNA was sonicated and 
then labeled with the Cy5 (experimental) and Cy3 (reference) AlexaFluor dyes using the 
BioPrime Plus labeling kit (Invitrogen, Carlsbad, CA). Two µg of reference and 
experimental DNA were hybridized onto the arrays (Agilent Technologies, Santa Clara, 
CA).  The arrays were scanned using an Agilent DNA Microarray Scanner (2-µm 
settings and 0.05 XDR).  Fluorescent intensity values were calculated using Agilent’s 
Feature Extraction 10.5 software (Agilent).  Copy number variants, including their 
corresponding log2 ratios, were identified using Agilent’s Genomics  
Workbench 7.  Copy number variants were called using the ADM-2 algorithm and the 
following filters: minimum probe span ≥ 3 and average log2 ratio ≥ 0.5, removal of 
probes with ≥ 3 standard deviations above or below the mean log2 fluorescent intensity.  
 
Logistic regression modeling was used to perform 2 separate CNV-based GWAS.  The 
first approach modeled the association of the binary outcome of 2 groups (e.g., clinical 
versus subclinical) with the log2 ratio of intensity values (a continuous variable) for each 
CNV.  The second approach modeled the association of the binary outcome of 2 groups 
with the presence or absence of a CNV (a binary categorical variable) within a CNV 
region.  For the first approach, CNV regions (CNVRs) were determined for the foals 
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examined.  The CNVRs were then filtered to include only CNVs identified in at least 3 
foals.  The log2 ratios of probes within each CNVR were then averaged to calculate a 
single log2 (CNVR-log2 ratio) for each CNVR for each foal. The CNVR-log2 values 
were used in a logistic regression model to identify associated CNVs among the pairwise 
comparisons of the 3 groups (case-control design described above).  For the second 
approach, a logistic regression model involving the binary outcome of presence (or 
absence) of a CNV within each CNVR was used to identify associated CNVs among the 
pairwise comparisons of the 3 groups.   For both approaches, the generated P values 
from linear modeling or regression analyses were corrected for multiple comparisons 
using the method outlined by Hochberg et al. 125.  Statistical analyses were performed 
using R (Version 3.0.1; R Statistical Project).  All CNV data have been deposited in 
NCBI's Gene Expression Omnibus (GEO) 122 and are accessible through GEO Series 
accession number GSE57510 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57510).  
 
Results 
SNP-based GWAS 
Three case-control GWAS were performed among the 24 randomly selected foals 
representing each group (clinical group, subclinical group, and unaffected group; Figure 
2.1).  The number of SNPs excluded on the basis of missingness per individual, 
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Figure 2.1. GWAS study population.  Schematic diagram representing the distribution of 
the total population into the 3 subgroups (R. equi pneumonia foals [clinical], subclinical 
foals, and unaffected foals), and by genome-wide association studies versus PCR 
genotyping for TRPM2 SNP.  The 3 comparisons among groups are also summarized.
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missingness per SNP, and minor allele frequency were 0, 1,292, and 11,157, respectively 
(12,449 total SNPs).  For comparisons 1, 2, and 3 (Figure 2.1), the number of SNPs 
excluded on the basis of Hardy-Weinberg equilibrium were 0, 83, and 54, respectively.  
After filtering, the total genotyping rate of the foals was estimated at 99.4%. Comparison 
1 (clinical [N = 24] vs. subclinical + unaffected [N = 48]; λ = 1.16) identified 7 regions 
showing evidence of moderate association with clinical pneumonia (P < 1 x 10-5) (Figure 
2.2 A and Table 2.1). Comparison 2 (clinical [N = 24] vs. subclinical [N = 24]; λ = 1.00 
[Supplementary Figure 2.1 A]) identified 10 regions with moderate association (Figure 
2.2 B and Table 2.1). The region associated with clinical pneumonia had a (point-wise) 
value of EMP1 ≤ 0.0002.  Comparison 3 (clinical [N = 24] vs. unaffected [N = 24]; λ = 
1.44 [Supplementary Figure 2.1 B]) identified 2 regions with moderate association 
(Figure 2.2 C and Table 2.1).  Results from each GWAS comparison are provided in 
Supplementary Table 1.   
 
The λ value of comparison 3 (1.44) suggested evidence of confounding population 
structure from 1 of the groups, thus mixed-effects modeling with sire as the random 
effect term was used as an additional association test.  There were 23,318 SNPs filtered 
due to failure to converge in mixed modeling, leaving 40,843 SNPs for evaluation in 
comparison 3.  The logistic mixed-effects modeling reduced the λ from 1.44 to 1.10 
(Supplementary Figure 2.1 D), and inspection of the observed versus expected P value 
plot indicated that none of the smallest P values [highest –log10 P values] observed were 
greater than expected (Figure 2.2 D and Supplementary Table 2.1).  The mixed-effects 
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model analysis identified 1 region with modest evidence of association (BIEC2_284540; 
chr15:7,394,044; P = 9.0 x 10-5).  The λ values of each comparison suggested the 
population structure was attributable to foals in the unaffected group because the 
magnitude of λ was greatest for the comparison of clinical versus unaffected groups (i.e., 
strongest evidence of population stratification), was 1.00 for clinical versus subclinical 
groups (i.e., absence of population stratification), and 1.14 when the clinical group was 
compared with the combination of healthy and subclinical (indicating the healthy group 
contributed to evidence of population stratification for this comparison).  
 
A region on chromosome 26 (chr26:39,640,172-39,867,963) showed evidence of 
association with clinical pneumonia (Comparisons 1 and 2), with the strongest evidence 
of association in comparison 2.  Three of the 4 SNPs identified in this region were 
BIEC2_732054, BIEC2_696979, and BIEC2_696992, with the first lying in a keratin-
associated protein (KRTAP) gene and the remaining 2 SNPs lying in non-genic locations.  
The region also contained a potential candidate gene (TRPM2) based on biological
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Figure 2.2. GWAS Manhattan plots.  Manhattan plots of standard chi-squared 
significance values for the 3 genome-wide association studies.  Manhattan plots for (A) 
comparison 1, (B) comparison 2, and (C) comparison 3; (D) Mixed effects-model 
analysis of comparison 3. 
 
 43 
 
Table 2.1. Moderately associated SNPs for each genome-wide association study. 
 
Comparison 1 
SNP ID Chromosomal location P Value Odds Ratio 
BIEC2_921509 5:79290169 2.21E-05 0.2 
BIEC2_1137861 9:19578673 4.42E-05 9.556 
BIEC2_976727 5:91479639 5.10E-05 0.09677 
BIEC2_650473 24:41033593 5.16E-05 0.04274 
BIEC2_732054 26:39777632 6.78E-05 12.05 
BIEC2_696979 26:39861109 6.78E-05 12.05 
BIEC2_696992 26:39867963 6.78E-05 12.05 
BIEC2_492054 2:80197359 7.73E-05 0.2036 
BIEC2_240596 13:31572932 8.94E-05 0.156 
BIEC2_825623 30:20687203 9.79E-05 0.2369 
BIEC2_867975 30:20690855 9.79E-05 0.2369 
Comparison 2 
SNP ID Chromosomal location P Value Odds Ratio 
BIEC2_732054 26:39777632 5.54E-06 17.89 
UKUL3936 26:39640172 9.93E-06 12.69 
BIEC2_696979 26:39861109 1.24E-05 16.43 
BIEC2_696992 26:39867963 1.24E-05 16.43 
BIEC2_16162 1:35593058 5.80E-05 13.8 
Comparison 3 
SNP ID Chromosomal location P Value Odds Ratio 
BIEC2_927543 5:88617368 1.63E-05 0.1486 
BIEC2_311792 15:54419913 1.75E-05 0.1515 
BIEC2_284540 15:7394044 2.21E-05 0.08571 
BIEC2_240596 13:31572932 2.41E-05 0.1163 
BIEC2_858227 30:6939831 2.99E-05 0.1512 
BIEC2_1078504 9:19582539 3.37E-05 0.1314 
BIEC2_310113 15:51485703 3.57E-05 0.1074 
BIEC2_310214 15:51596762 3.57E-05 0.1074 
BIEC2_324522 15:51634407 3.57E-05 0.1074 
BIEC2_921509 5:79290169 4.19E-05 0.1667 
BIEC2_784299 3:59782881 4.45E-05 0.1445 
BIEC2_239002 14:3055273 4.46E-05 0.1696 
BIEC2_976312 5:90703095 4.80E-05 0.09333 
BIEC2_928796 5:90706671 4.80E-05 0.09333 
BIEC2-815626 30:5321760 7.70E-05 0.1169 
BIEC2_784331 3:59874438 7.87E-05 5.8 
BIEC2_784332 3:59874495 7.87E-05 5.8 
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Table 2.1. Continued 
BIEC2_869756 4:72076243 7.87E-05 5.8 
BIEC2_435811 19:33380654 8.85E-05 0.1784 
BIEC2_1137861 9:19578673 9.20E-05 10.09 
 
 
function 54 identified by the SNP marker, UKUL3936 (P = 9.93 x 10-6; OR = 12.7), 
which was also located within exon 22 of the TRPM2 gene.  On the basis of this finding, 
a joint analysis was performed to include results of PCR-based genotyping of the 
UKUL3936 SNP for the samples from the larger remaining population of foals not 
included in the GWAS study (i.e., clinical [N = 19], subclinical, [N = 132], and 
unaffected [N = 25]).  Prior to performing the joint analysis, 10 of 72 foals previously 
genotyped on the SNP array were used to validate the genotyping reaction used for the 
joint analysis; results of SNP array and PCR genotyping agreed for all 10 foals. The joint 
analysis comparing clinical versus subclinical foals (comparison 2) revealed that foals 
from the clinical group were approximately 4-fold less likely to have either an AB 
(1/(0.23) = 4.3; P = 0.0017) or BB genotype (1/(0.28) = 3.6, P = 0.0574), consistent with 
a dominant model, possibly with partial penetrance (Table 2.2).  Considering just the AA 
genotype relative to the other  
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Table 2.2. Joint analysis of TRPM2 SNP UKUL3936 
Genotype  
Standard Model Clinical foals  Subclinical foals P value Odds Ratio (95% 
CI) 
AA 72% (31/43) 41% (64/156) NA 1 (NA) 
AB 23% (10/43) 47% (74/156) 0.0017 0.28 (0.13 to 0.61) 
BB   5% (2/43) 12% (18/156) 0.0574 0.23 (0.05 to 1.04) 
  
Dominant Model  
Not AA 28% (12/43) 59% (92/156)  NA 1 (NA) 
AA 72% (31/43) 41% (64/156) 0.0006 3.71 (1.78 to 7.76) 
 
Additive Model  
f(A)* 2(0 to 2) 1(0 to 2) 0.0014 2.83 (1.51 to 5.31) 
 (72/86) 84% (202/312) 65%   
* Median (range) reported for frequency of allele A, along with the proportion of A alleles among all 
alleles represented for each group.  Joint analysis includes genotypes derived from SNP array and 
PCR genotyping. 
 
 
genotypes, the odds of disease were approximately 3.7-fold greater for foals with the AA 
genotype (Table 2.2; P = 0.0006). Using an additive model, there was a significant (P = 
0.0014) association of the A allele in comparisons between the clinical and other groups, 
with an estimated odds of a clinical classification being increased nearly 3-fold for each 
copy of the A allele.  Examination of the genotype data, however, suggested an additive 
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model was unlikely: the ORs for the AB and BB types relative to the AA genotype were 
similar.  The AA genotype of the TRPM2 gene also was significantly associated with 
increased odds of R. equi pneumonia when considering the results of comparisons of the 
clinical foals versus all foals (comparison 1; Supplementary Table 2) and for clinical 
foals versus healthy foals (comparison 3; Supplementary Table 2.3), irrespective of the 
genetic model.  
 
CNV-based GWAS 
Next, array aCGH was performed to genotype CNVs in the 72 foals examined in the 
SNP-based GWAS.  Two reactions failed to meet the minimum quality scores for CNV 
detection, so they were excluded from the study (foals 153 and 278).  Collectively, 6,727 
CNVs were identified among the 70 foals (Table 2.3 and Supplementary Table 2.3).  
Merging shared CNVs yielded 2,350 CNV regions (CNVR) that were present at 3,492 
Ensembl annotated genes (3,442 protein-coding and 50 RNA-coding). The lengths of 
CNVs ranged from 197 base-pairs (bp) to 7,229.5 kilo-bp (kb), with a mean length of 
97.7 kb, median length of 4.4 kb, and mode length of 960 bp.    
 
The association between disease status (the outcome variable) and individual CNVs 
(dependent variable) was assessed using logistic regression analysis.  Because CNV 
genotypes reflect 
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Table 2.3. CNVs identified in each clinical group. 
 Clinical foals Subclinical foals Unaffected foals P Value 
Total CNVs 84 (29 to 592; 2,654) 57 (29 to 338; 
1,823)  
77 (28 to 254; 2,250) 0.262 
Gains 25 (8 to 395; 1,229) 24 (9 to 187; 770) 30 (10 to 152; 957) 0.334 
Losses 41 (15 to 197; 1,425) 36 (16 to 151; 
1,053) 
40 (16 to 139; 1,293) 0.574 
CNVs: median (range; sum); Kruskal-Wallis test 
 
 
 
 
Table 2.4. Top 5 CNV regions identified using logistic regression for the association of 
R. equi with either the binary variable presence or absence of a CNV identified in the 
region (Presence column) or the log2 ratio of intensity values of the CNVs (Intensity 
columns).   
 
Presence Intensity (log2) 
CNVR Location CNVR Location 
232 chr1:158563545-160296515 179     chr1:135750728-135756968 
237     chr1:161277315-161277884 391     chr2:88754970-89061174 
269     chr2:6304157-6378969 458 chr3:36530104-36530453 
536     chr4:21281685-23733388 645     chr5:40060212-40060524 
735 chr6:42263179-42282649 753 chr6:59580727-59585139 
CNVR identification numbers are provided in Supplementary Table 1. 
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differences in DNA content between 2 individuals and are expressed as normalized log2 
ratios representative of varying degrees of copy number gains and losses, separate 
logistic regression modeling was performed using CNVs as the dependent variable as 
either 1) continuous variables representing average log2 ratios of CNVRs or 2) a binary 
variable representing the presence or absence of a given CNV (see Materials and 
Methods section).  Comparisons among groups of foals were made in the CNV-based 
GWAS as described above (Figure 2.1).  Correction for multiple comparisons revealed 
no significant (P < 0.05) associations of disease with CNVs when considered as 
continuous log2 ratios (Table 2.4) or as the binary outcome for presence or absence of a 
CNV.  No association with clinical status grouping was detected on the basis of the total 
number of CNVs for individuals (Table 2.3).   
 
Discussion 
Rhoddococcus equi is an important cause of disease and death in young foals 6.    
Multiple factors such as age, environmental conditions including level of exposure to 
virulent organisms, and genetic background appear to play a role in the occurrence of 
this complex disease 126-128.  The purpose of this study was to better characterize the 
genetic basis of susceptibility to R. equi pneumonia.  One special feature of this study 
was the phenotypic characterization of foals into those that remained unaffected (i.e., 
free of both clinical signs and ultrasonographic evidence of disease) through weaning, 
those that had subclinical pneumonia (i.e., absence of clinical signs but ultrasonographic 
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evidence of pulmonary lesions), and those that developed R. equi pneumonia. At most 
farms where screening is performed, foals with evidence of subclinical pneumonia 
receive treatment or other interventions that precludes one from differentiating foals that 
would have progressed to clinical disease from those that would have remained 
subclinical.  At the farm described in this report, however, foals with subclinical 
pneumonia were not treated or otherwise managed differently than unaffected foals 
providing us with the exceptional opportunity to conduct GWAS’s with 3 clinically 
important phenotypes.    
 
A SNP-based GWAS revealed a region on chromosome 26 (chr26:39640172-39867963) 
that was positively associated with disease.  This region contains the TRPM2 gene, 
which is associated with neutrophil function.  Although, TRPM2 is an ideal candidate 
based on its known biological function, an adjacent SNP located within the KRTAP gene 
was more strongly associated than the SNP located with TRPM2.  Further, investigation 
of this region (e.g., fine-mapping of the region) is needed before any conclusion can be 
made regarding the role of TRPM2 in R. equi pneumonia. Nevertheless, TRPM2 is of 
interest because it has been demonstrated in mice to play a role in neutrophil-mediated 
tissue damage 54.  Neutrophils have been shown to play an important role in the outcome 
of R. equi infection.   Neutrophil-depleted mice had significantly heavier tissue burdens 
of R. equi following experimental infection than non-depleted mice, documenting a 
protective role for neutrophils 129.  The neutrophil concentrations at 2 and 4 weeks of age 
were significantly lower among foals that subsequently developed R. equi pneumonia 
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than among age-matched foals that did not develop pneumonia 130.  Similar protective 
roles for neutrophils have been documented for other intracellular pulmonary pathogens 
129,131,132.  Moreover, R. equi has an age-dependent distribution (i.e., foals are usually 
affected and adults are generally resistant to infection), and age-related differences in 
neutrophil responses to R. equi have been documented 133-135.  Although neutrophils play 
a role in protecting against R. equi infection, they also contribute to lung parenchymal 
damage of this pyogranulomatous disease 6,136. In a mouse model of ulcerative colitis, 
the over-abundance of neutrophil invasion into tissue mediated by TRPM2 expression, 
led to increased colonocyte death 54.  Thus, variation in TRPM2 expression could 
influence the extent to which neutrophil-induced pulmonary damage occurs following 
infection with R. equi, and this variation could be a crucial determinant of the clinical 
outcome of infection with R. equi and the progression from subclinical to clinical 
pneumonia.  If the TRPM2 allele implicated in our study were associated with increased 
TRPM2 expression, it might consequently be associated with greater likelihood of 
pneumonia development as a result of greater neutrophil invasion.  The functional 
effects of this TRPM2 genotype are unknown, however.  Interestingly, expression of a 
splice variant of TRPM2 was demonstrated to inhibit death of several cultured cell lines 
137.  Further evaluation of the functional differences in neutrophilic responses among 
TRPM2 genotypes is warranted. 
 
A CNV-based GWAS was conducted and revealed no significant association with 
disease status.  Despite the negative findings, these results are of interest with regard to 
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better characterizing genetic variation in horses and using CNVs for GWAS with disease 
outcomes.   A search of PubMed reveals no other attempt to perform a CNV GWAS via 
aCGH in horses and to the authors’ knowledge no others have been done.  Valuable 
information was gained in terms of the analysis of CNV data generated from a GWAS 
using aCGH.  The identification of CNVs is based on log2 ratios of intensity signals that 
are generated between the reference and sample DNA.  The results may be interpreted 
either as presence or absence of a CNV, based on a threshold intensity value 71, or the 
actual intensity values themselves.    As observed in this study, these 2 outcomes for 
CNV-calling yielded differing results.  We propose that utilizing average log2 ratios 
across CNV regions is superior because classification of CNVRs by presence or absence 
does not further characterize a CNV, whereas analysis of the log2 ratios allows for the 
identification of whether the CNV involved gains or losses, and for description of the 
magnitude of the gain or loss.   
 
We failed to identify significant association with candidate genes previously associated 
with R. equi pneumonia in other breeds of foals 19,29,30.  This may have been attributable 
to differences among populations of foals studied (e.g, breeds) or study methodology 
(e.g,, case definitions, methods for detecting polymorphisms, etc.).   Nevertheless, a 
commonality among these studies can be found in their identification of genes pertaining 
to host defenses against infectious pathogens, such as iron transport and innate immune 
responses.  Conceivably, these apparently discrepant findings may converge on critical 
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biological pathways or processes that influence susceptibility to infection with R. equi 
(and other intracellular pathogens). 
    
This study had a number of limitations.  First, it was likely underpowered for both the 
SNP- and CNV-based GWAS portions of the study: we only had the opportunity to find 
SNPs or CNVs with large effects.  This lack of power is probably why we did not 
identify highly significant associations in the SNP-based GWAS for 2 of our 3 
comparisons (Figure 1), and only moderate significance for the allele identified in 
comparison 2.  Although sample sizes may be calculated for human studies, methods for 
incorporating crucial determinants of sample size such as the impact of the relatively 
longer length of linkage disequilibrium in horses relative to humans remain to be 
defined.  Moreover, the cost of GWAS studies and the limited funding available for 
equine research can be restrictive.  It is worth noting that our SNP-based GWAS did 
provide sufficient power to identify a SNP associated with R. equi that was subsequently 
substantiated by findings of the joint analysis using PCR testing of additional foals from 
this population for all 3 comparisons.  Nevertheless, larger scale studies are indicated.  
For example, 1 locus on chromosome 15 (in the promoter region of a chemokine) was 
weakly associated in both the mixed-effects modeling and standard GWAS analyses for 
comparison 3: this finding could be simply attributable to chance but also could 
represent an underpowered association that merits further investigation.    
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A limitation of this study is that it was restricted to foals of a single breed at a single 
farm.  Further studies are indicated to substantiate whether the observed association 
holds among other Quarter Horse foals at other farms, and among foals of other breeds.  
Another limitation was that although the mixed modeling for comparison 3 yielded a 
marked reduction in the estimated value of λ (from 1.44 to 1.10), the mixed modeling 
value of λ suggested residual confounding from population structure.  Graphical analysis 
of the results of mixed modeling, however, suggested this was not the case: the plot of 
observed versus expected P values indicated that fewer than expected small P values 
were identified and more than expected large P values were observed following mixed-
effects modeling, and Manhattan plots of the standard and mixed-effects model GWAS 
for comparison 3 revealed a shift to larger P values following mixed-effects modeling 
(Supplementary Figure 2.1).  Moreover, the linear regression-based estimate of λ had a 
poor fit because the data were non-linear in the range of the high P values (data not 
shown).  We interpreted these results to indicate that the mixed-effects modeling had 
largely corrected for population stratification attributable to sire, and that the study was 
underpowered.  As noted, a limitation of this study is that we lack fine-mapping of the 
region to determine whether the TRPM2 allele is a causal variant or simply in linkage 
disequilibrium with another gene or genes that contribute to susceptibility to R. equi.  
Finally, it must be noted that although the estimated OR for the TRMP2 SNP was 
relatively large, it is not of sufficient magnitude to be clinically useful for screening 
purposes.   
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Despite the aforementioned limitations, this study has identified a region on 
chromosome 26 that was associated with R. equi pneumonia in foals, and the largest 
scale GWAS in foals reported to date.  Furthermore, it extends current knowledge of 
equine CNVs and analysis of data from GWAS using aCGH in horses. 
 
Conclusions 
In conclusion, the results of this study identify a locus and gene potentially involved in 
the development of R. equi pneumonia in foals.  Future studies are warranted to 
substantiate the association of TRPM2 gene (and related pathways) with R. equi 
pneumonia and to provide fine-mapping of the region on chromosome 26 implicated in 
this GWAS.   
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CHAPTER III 
USE OF RNA-SEQUENCING TO INVESTIGATE FUNCTIONAL IMPLICATIONS 
OF RHODOCOCCUS EUQI ASSOCIATED GENTOYPES 
 
Introduction 
Rhodococcus equi is a pathogen that predominantly affects young foals causing 
pneumonia as well as extrapulmonary disorders 1,6,53,97,116.  Currently, there is no 
approved or effective vaccine for protection against R. equi pneumonia, and other 
preventative interventions, such as transfusion of hyperimmune plasma, are expensive, 
labor-intensive, and incompletely effective 3,6.  Evidence has shown that R. equi taken up 
by the host must bear the virulence associated protein A (VapA) gene in a plasmid in 
order to cause disease; however, presence of the plasmid and VapA alone is not 
sufficient to cause disease indicating host factors are of great importance 7,8.  In addition 
to anecdotal reports of some mares having multiple infected foals while other mares in 
the same environment never have an affected foal, several candidate gene studies 
suggest a genetic basis of R. equi susceptibility and have been reviewed 19,22,29,30,138.  
Due to gene selection biases and phenotypic misclassification, the associations from 
candidate gene studies have been weak and potentially biased 17.  
 
Recently, our laboratory identified a region on chromosome 26 associated with R. equi 
pneumonia in a genome-wide association study (GWAS)[15] using a commercially 
available SNP array 39,52.  Four SNPs were associated with clinical disease in a region 
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spanning several predicted genes.  One of the SNPs was well suited to serve as a marker 
because it was located within the transient receptor potential cation channel, subfamily 
M, member2, candidate gene (TRMP2) and could be easily and accurately genotyped 52.  
This SNP was associated with 3 genotypes designated AA, AB, and BB alleles.  Because 
SNPs are merely indicators of location and are very rarely actual causal mutations, it 
remains unclear which genes in this region might explain the observed association of 
genotype with disease.  More importantly, these SNPs alone do not provide any 
functional information regarding the relationship between genotype and phenotype 
across this region.  The marker SNP in TRPM2 is a synonymous substitution and does 
not change the amino acid or protein sequence.  Thus, other approaches such as 
investigating gene expression are necessary to further investigate the observed 
association of the TRPM2 SNP and R. equi pneumonia.   
 
Investigating the whole transcriptome (i.e., the entire translated genome) using RNA-Seq 
provides an unbiased approach for gene expression analysis because all potential genes 
and their isoforms are considered 139 yielding greater possibility for identifying true 
expression phenotypes associated with the genotype(s) of interest.  Using RNA-Seq 
enables the characterization of the transcriptional activity across the region of interest 
(i.e., targeted analysis) as well as across the remainder of the genome (i.e., untargeted 
analysis), such as differences in total expression of genes, alternatively spliced 
transcripts, and truncated gene transcripts.  Thus, we used RNA-Seq to perform targeted 
and untargeted associations of gene expression with both genotype and phenotype 
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previously associated with R. equi infection.  For our targeted approach, we determined 
which genes in the region of interest on chromome 26 were expressed differentially by 
each of the 3 marker genotypes identified for the TRPM2 SNP (i.e., AA, AB, or BB 
alleles) as well as to identify associations between gene expression profiles and clinical 
phenotypes (Supplementary Figure 3.1).  In addition to our targeted analysis, we also 
examined genes differentially expressed across the entire transcriptome to look for other 
genes that were differentially expressed that might be associated either with genotype or 
with susceptibility to R. equi pneumonia.  The objectives of this study were to identify 
biological pathways and processes involved in susceptibility to R. equi pneumonia as 
well as to characterize the Quarter Horse transcriptome 86,87,94.     
  
Materials and methods 
Study population 
All protocols for this study were reviewed and approved by the Institutional Animal 
Care and Use Committee (AUP: IACUC 2013-0259 CA, Approval Date: 1/29/2014).  
Written informed consent for participation was obtained for all horses included in the 
study, and the 6666 Ranch provided access to the horses for use in this project.  The 
study population was derived from the source population for our GWAS described 
above (viz., foals born during 2011 at the 6666 Ranch) 52, which had a cumulative 
incidence of R. equi pneumonia of 17% during 2011.  We identified 51 horses still 
remaining at the 6666 Ranch that had been foals during our previous study in 2011; 
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horses (formerly foals) of each of the 3 genotypes of interest (i.e., AA, AB, and BB) 
identified from our GWAS were available for testing.  Foals were randomly selected for 
participation in the RNA-Seq portion of this study which included 3 AA, 4 AB, and 5 
BB genotypes.  This sample size was determined by the funding available for this project 
and the cost of RNA-Seq. 
 
Sample collection and RNA-Seq 
A whole blood sample (5 mL) was collected by jugular venipuncture into 2 Paxgene 
RNA Vaccutainer tubes (PreAnalytiX, Hombrechtikon, Switzerland) at the 6666 Ranch, 
Guthrie, TX, June 25, 2014, to permit the RNA to be stabilized for transport to Texas 
A&M University.  The blood samples were processed with the MagMax Paxgene RNA 
purification kit (Life Technologies) to isolate total RNA.  The Texas A&M Agrilife 
Genomics and Bioinformatics facility constructed a cDNA library using the TrueSeq 
RNA preparation kit (Illumina) with a polyA selection step,and performed RNA-Seq.  
Samples were pooled and sequenced in duplicate (2 lanes) on a HiSeq 2500 (Illumina) to 
account for any lane biases that might arise.  The HiSeq2500 generated 125-base-pair 
(bp) paired-end (PE) sequencing reads for expression analyses.   
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 Gene expression analysis for genotypic and phenotypic comparisons (targeted and 
untargeted) 
 Raw data output of the RNA-Seq was processed by our laboratory using multiple online 
resources provided by the Texas A&M Institute for Genome Sciences and Society.  The 
generated PE reads were aligned to the entire equine genome reference sequence 
(Equcab2) using Tophat 84.  Aligned reads were then mapped to equCab2 ENSEMBL 
gene annotation and read counts assigned to each sample at each gene using HTSeq 140.  
HTSeq generated count tables using the intersection nonempty parameter to account for 
ambiguous reads (i.e., overlapping reads that map to overlapping genes).  
 
Three comparisons were chosen to test for differentially expressed genes within the 
horses.  The first comparison made was between the AA genotyped foals (n = 3) and the 
non-AA genotyped foals (i.e., the combined total of AB and BB genotyped foals (n = 
9)).  The AB and BB genotypes were combined on the basis of our previous results 
indicating that the odds of disease were equivalently greater in the AA homozygotes 
relative to the AB genotype, the BB genotype, or their combination 52.  The next 
comparison tested for differential expression among the 3 genotypes (viz., AA, AB, and 
BB) to identify any genes differentially expressed relative to each genotype.  A third 
comparison tested for differential gene expression between horses that had clinical cases 
of R. equi pneumonia as foals (n = 2) and horses that had not developed clinical signs of 
pneumonia as foals (i.e, subclinical pneumonia or no pneumonia; n = 10).  All analyses 
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were performed using R statistical software (Version 3.0.1; R Statistical Project), the 
edgeR package, and cuffdiff 84,141-145.  All normalizations and calculations were 
performed using the recommended pipeline per the edgeR and Tophat authors’ 
instructions.  Briefly, the HTSeq generated count table was filtered to remove genes to 
which 0 reads mapped in all samples.  In edgeR the tabulated read counts were then 
normalized and tag-wise and common dispersions estimated.  Differentially expressed 
genes were defined as those genes having a false discovery rate (FDR) ≤ 0.05 that were 
identified with the exactTest function.  The cuffdiff function of the Tophat tool suite was 
used to calculate differentially expressed genes using the default settings with the 
accepted_hits.bam file from the Tophat mapping step used as input.   Genes having a q-
value (FDR) ≤ 0.05 were considered differentially expressed.   Cuffdiff was only used to 
test for differential expression using the AA vs. AB/BB and genotypic pairwise 
comparisons described above.   
 
Biological pathway analysis was performed using the Ingenuity Pathway Analysis (IPA) 
(Qiagen, Venlo, Netherlands; www.ingenuity.com) tool-kit.  Output files from both 
edgeR and cuffdiff were used in their respective pathway analyses.  Input files for IPA 
used the following information from the edgeR or cuffdiff outputs: a column containing 
an Ensembl gene identifier, a corresponding RefSeq gene name where applicable, the 
log fold change of expression for each gene between the 2 groups tested, and a FDR for 
each gene tested. 
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Visualization of RNA-Seq read coverage across the region of interest was carried out 
using BEDTools and the UCSC online genome browser by assigning reads from the 
accepted_hits.bam output files from the previously described Tophat mapping step 
146,147.  Based on evidence from visualization of the RNA-Seq reads, transcript variation 
across the region of interest (viz., chr26; targeted analysis) was also assessed.  The 
cufflinks function of the Tophat tool suite was used to identify alternatively spliced and 
novel transcripts at the TRPM2 locus 84.  Briefly, cufflinks does not use an annotation to 
map and calculate read counts at genes, rather it uses a de novo approach for calculating 
transcripts and isoforms prior to mapping reads to an annotation.   
Targeted TRPM2 analysis was performed by using the datasets generated from the 
cuffdiff comparisons previously described.  Cuffdiff generates output files containing the 
transcript (gene, encompassing all isoforms) abundances and isoform (alternatively 
spliced transcripts) abundances which were extracted and expression level compared for 
specific individual transcripts.  
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Table 3.1. Transcriptome-wide differentially expressed genes identified by edgeR 
analysis. 
Ensembl ID RefSeq ID Log FC Log CPM P Value FDR 
ENSECAG00000022239 ANKRD22 -5.82 0.23 0.0000 0.0000 
ENSECAG00000006492 DQB -2.00 7.30 0.0000 0.0028 
ENSECAG00000006662 MPO -3.22 -0.44 0.0000 0.0483 
ENSECAG00000017147 C15orf52 -3.08 -1.66 0.0000 0.0968 
ENSECAG00000002249 PLEKHG4B -4.64 -1.57 0.0000 0.0983 
ENSECAG00000008171 N/A -3.80 -0.68 0.0000 0.1476 
ENSECAG00000008238 S100A5 -3.41 -1.98 0.0001 0.1476 
ENSECAG00000016666 OMG 0.89 6.37 0.0001 0.2650 
ENSECAG00000006656 N/A -3.08 -2.89 0.0002 0.4258 
ENSECAG00000024043 CSTA -2.09 2.50 0.0003 0.4904 
 
 
 
Table 3.2. Transcriptome-wide differentially expressed genes identified by cuffdiff 
analysis. 
Ensembl ID RefSeq ID Log2 FC P value Q Value Significant 
ENSECAG00000024043 CSTA -2.08 0.0001 0.0122 yes 
ENSECAG00000024259 DQA -1.83 0.0001 0.0122 yes 
ENSECAG00000019922 ADAMDEC1 -1.39 0.0001 0.0122 yes 
ENSECAG00000009142 DQA -1.34 0.0001 0.0122 yes 
ENSECAG00000020816 PDLIM1 -1.32 0.0001 0.0122 yes 
ENSECAG00000015109 N/A -1.28 0.0001 0.0122 yes 
ENSECAG00000012883 CEBPE -1.27 0.0001 0.0122 yes 
ENSECAG00000023062 N/A -1.26 0.0001 0.0122 yes 
ENSECAG00000019130 SIRPG -1.22 0.0001 0.0122 yes 
ENSECAG00000011315 EMR3 -1.17 0.0001 0.0122 yes 
ENSECAG00000013660 C1orf186 -1.16 0.0002 0.0371 yes 
ENSECAG00000025078 SUSD2 -1.05 0.0001 0.0122 yes 
ENSECAG00000016730 CSMD1 -0.99 0.0001 0.0122 yes 
ENSECAG00000001282 CCR3 -0.95 0.0001 0.0122 yes 
ENSECAG00000008322 GZMH 0.79 0.0002 0.0371 yes 
ENSECAG00000007621 TRIP11 0.86 0.0003 0.0435 yes 
ENSECAG00000018564 SPATS2L 0.87 0.0001 0.0221 yes 
ENSECAG00000019111 CD163 0.89 0.0002 0.0308 yes 
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Table 3.2. Continued      
ENSECAG00000020763 MGST1 0.91 0.0001 0.0221 yes 
ENSECAG00000014422 OAS2 0.92 0.0001 0.0122 yes 
ENSECAG00000011776 MX1 0.93 0.0001 0.0221 yes 
ENSECAG00000021989 DDX58 0.94 0.0002 0.0308 yes 
 
ENSECAG00000003474 TTLL3 0.94 0.0001 0.0122 yes 
ENSECAG00000001399 SAMD9 1.03 0.0001 0.0221 yes 
ENSECAG00000014218 SIGLEC1 1.04 0.0003 0.0435 yes 
ENSECAG00000008274 CLEC4E 1.05 0.0001 0.0122 yes 
ENSECAG00000010117 S100A9 1.05 0.0001 0.0122 yes 
ENSECAG00000013762 NCR1 1.07 0.0002 0.0308 yes 
ENSECAG00000023733 MMP-1 1.10 0.0001 0.0221 yes 
ENSECAG00000015006 FGFR1 1.10 0.0003 0.0435 yes 
ENSECAG00000007133 TPPP3 1.11 0.0001 0.0122 yes 
ENSECAG00000022042 PNP 1.11 0.0001 0.0122 yes 
ENSECAG00000008356 ZNF577 1.15 0.0003 0.0435 yes 
ENSECAG00000012235 BAZ2B 1.15 0.0001 0.0122 yes 
ENSECAG00000009742 S100A12 1.15 0.0001 0.0122 yes 
ENSECAG00000021476 MMP8 1.16 0.0001 0.0122 yes 
ENSECAG00000009271 S100A8 1.18 0.0001 0.0122 yes 
ENSECAG00000019411 HERC6 1.20 0.0001 0.0122 yes 
ENSECAG00000026820 SEPP1 1.22 0.0001 0.0122 yes 
ENSECAG00000007881 IFIH1 1.24 0.0001 0.0122 yes 
ENSECAG00000014645 OASL 1.29 0.0001 0.0122 yes 
ENSECAG00000010153 IFIT4 1.33 0.0001 0.0122 yes 
ENSECAG00000013874 SPARC 1.44 0.0002 0.0308 yes 
ENSECAG00000001481 SAMD9L 1.47 0.0001 0.0122 yes 
ENSECAG00000008809 OAS3 1.51 0.0001 0.0122 yes 
ENSECAG00000000500 IF16 1.53 0.0001 0.0122 yes 
ENSECAG00000015395 HERC5 1.54 0.0001 0.0122 yes 
ENSECAG00000001324 ISG15 1.55 0.0001 0.0122 yes 
ENSECAG00000008594 BTN3A1 1.59 0.0001 0.0122 yes 
ENSECAG00000006913 N/A 1.90 0.0001 0.0122 yes 
ENSECAG00000019949 CYP4F 1.92 0.0001 0.0122 yes 
ENSECAG00000017437 MYLPF 2.38 0.0002 0.0371 yes 
ENSECAG00000004349 IFIT5 2.54 0.0001 0.0122 yes 
ENSECAG00000020407 MYBPC2 2.64 0.0002 0.0371 yes 
ENSECAG00000010020 HBB 2.73 0.0001 0.0122 yes 
ENSECAG00000023971 TNNT3 4.46 0.0002 0.0371 yes 
ENSECAG00000019728 TNNC2 5.11 0.0001 0.0122 yes 
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Table 3.2. Continued      
ENSECAG00000005487 N/A 8.08 0.0001 0.0122 yes 
 
 
Results 
Transcriptome-wide differential gene expression (untargeted analysis) 
RNA-Seq read counts were generated for each sample at all gene loci using the 
ensemble gene annotation reference resulting in counts for all samples at 26,991 genes.  
We removed 8,212 genes for which all samples had 0 reads mapped, leaving 18,779 
genes for further analysis.  The first analysis performed was a comparison of the AA 
genotype foals and the non-AA genotyped foals.  This comparison revealed 3 genes 
(ANKRD2, DQB, and MPO; Table 3.1) that were identified as differentially expressed 
with an FDR ≤ 0.05.  All 3 of these genes were up-regulated in the AA genotyped foals.  
The second analysis of pairwise comparisons among the genotypes  (viz., AA vs AB, AB 
vs BB, and AA vs BB) did not identify any differentially expressed genes.  The third 
analysis comparing the 2 horses that had clinical pneumonia as foals and the 10 horses 
that had not developed clinical signs as foals revealed no differentially expressed genes.  
Cuffdiff was then used to test for transcriptome-wide differential gene expression 
between the AA and non-AA genotyped samples. The cuffdiff analysis identified 58 
differentially expressed genes with an FDR ≤ 0.05 (Table 3.2).  Inspection of the results 
from the 2 transcriptome-wide analyses comparing the AA with the non-AA genotypes  
 65 
 
 
 
Figure 3.1. Results of the pathway analysis.  TRPM2 was not identified as differentially 
expressed in the analysis but was added for the purpose of identifying TRPM2’s link 
with the differentially expressed genes.
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using edgeR and cuffdiff revealed that no genes were concordantly identified as being 
differentially expressed. Expression levels of DQB was closest to being differentially 
expressed (P = 0.00075, FDR = 0.108) in the cuffdiff analysis, with the ANKRD22 and 
MPO having FDRs of 0.73 and 0.63 respectively.   
 
Looking first at the 3 genes identified as differentially expressed in the edgeR analysis,  
IPA was unable to link ANKRD22, DQB, and MPO through any pathway.  Using the 58 
differentially expressed genes found in the cuffdiff analysis, IPA was able to build a 
pathway which linked the differentially expressed genes (Figure 3.1).  The top pathway 
identified included 17 of the differentially expressed genes and was related to host 
antimicrobial and inflammatory response as well as cell-to-cell signaling and interaction.  
One of the top up-regulated genes in the horses with AA genotypes compared to the non-
AA genotypes was CCAAT/enhancer binding protein epsilon (C/EBPE) which had a 
1.3-fold increase in expression over non-AA genotyped horses and was a critical 
component of the identified pathway structure.              
 
Targeted analysis 
Visualization of RNA-Seq coverage across the region on chromosome 26 was performed 
by creating bedgraphs (Figure 3.2 A) which revealed some potential novel transcripts, 
exons, and 3` UTRs.  These findings warranted further investigation within the region of 
interest as novel transcripts and isoform-specific expression were not accounted for in 
the transcriptome-wide analyses.   
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To identify novel exons and transcripts we used cufflinks to create a new gene model 
representing the region around and including TRPM2.  Transcriptome-wide, cufflinks 
assembled 34,294 transcripts and output generated was visualized in the UCSC genome 
browser. At the TRPM2 locus on chromosome 26, cufflinks output showed the program 
had assembled 2 distinct genes instead of the single TRPM2 gene currently annotated in 
the browser (Figure 3.2 B), that will be referred to as TRPM2-1 and TRMP2-2.  The 
currently annotated TRPM2 gene was broken by cufflinks into a novel predicted 
transcript starting upstream of the reference annotation (TRPM2-1).   The remainder of 
the currently annotated TRPM2 locus was incorporated by cufflinks into a novel 
independent transcript extending to the annotated 3` UTR of TRPM2 (TRPM2-2).  Using 
the 2 novel transcripts, TRPM2-1 and TRPM2-2, in place of the currently annotated 
TRPM2, we re-analyzed the RNA-Seq data.  The data were mapped with HTSeq using 
these 2 new coordinates for TRPPM2 and differential expression analysis performed 
with edgeR, and no differential expression identified.   
 
With this new gene model of TRPM2 (viz., TRPM2-1 and TRPM2-2) and using the 
cuffdiff function, we extracted only the read mapping to the new transcripts.  There was 
significant differential expression between the AA and AB genotypes with respect to the 
TRPM2-1 transcript (Table 3.3).  
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To investigate whether the genotypes were a marker for isoform expression differences 
we used the cuffdiff option in Tophat to analyze the sequencing data.  Our previous 
analysis assigned reads to overall genes and not isoforms, whereas cuffdiff also allows 
for reads to be assigned to isoforms in order to estimate transcript abundances.  When 
extracting only the reads for the 2 novel TRPM2 transcripts identified with cufflinks we 
identified 10 isoforms at the TRPM2-1 locus and 7 isoforms at the TRPM2-2 locus.  This 
analysis showed 1 significant difference in transcript abundances between the AA and 
AB genotypes at the novel TRPM2-1 and TRPM2-2 genes which corresponds with the 
above transcript differences (Table 3.3).  
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Table 3.3. Novel TRPM2 transcripts pairwise comparisons. 
Gene ID Transcript ID AA ABBB 
Log2 
FC 
P value Q value 
CUFF.23429 TRPM2-1 90.99 118.90 0.39 0.0971 0.9995 
CUFF.23430 TRPM2-2 168.23 214.17 0.35 0.1630 0.9995 
              
 
 
AA AB    
CUFF.23429 TRPM2-1 91.81 130.55 0.51 0.0224 0.9238 
CUFF.23430 TRPM2-2 169.73 225.94 0.41 0.0783 0.9997 
              
 
 
AA BB    
CUFF.23429 TRPM2-1 90.63 110.04 0.28 0.2663 0.9991 
CUFF.23430 TRPM2-2 167.57 205.44 0.29 0.2766 0.9991 
              
 
 
AB BB    
CUFF.23429 TRPM2-1 128.83 110.27 -0.22 0.3456 0.9999 
CUFF.23430 TRPM2-2 223.02 205.87 -0.12 0.6565 0.9999 
 
 
Discussion  
Biological implications 
The findings reported in this paper are an additional piece of highly compelling evidence 
of the role of the innate immune response and the subsequent host outcome after 
infection by R. equi.  As previously reported, TRPM2 markers have been shown to 
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associate with clinical disease caused by R. equi.  The TRPM2 gene was biologically 
plausible as a candidate gene because TRPM2 has been shown to increase tissue damage 
at sites of inflammation in a mouse model of ulcerative colitis 52,54.  Also, it has been 
demonstrated in vitro that a short isoform of TRPM2 inhibits calcium influx while 
increasing cell viability 137.  On the basis of these findings, we considered it important to 
understand the expression pattern across the region of interest identified in our previous 
GWAS.  We found evidence indicating that alternative splicing likely occurs within the 
TRPM2 locus in horses resulting in multiple isoforms.  Although we did not attempt to 
verify the functionality of these transcripts in horses, an alternative transcript has been 
functionally characterized in human-derived cell lines 137; thus it is plausible that these 
equine splice variants might differ functionally 137.  Considering the genes identified as 
being differentially expressed by cuffdiff, 1 gene was of great interest, viz., C/EBPE.  
The C/EBP gene and its isoforms are known to be expressed by human neutrophils and 
play an integral part in inducing several inflammatory cytokines 148.  C/EBP was shown 
to bind the promoter of interleukin 8 (IL-8, CXCL8) when stimulated by LPS and shows 
a direct link between C/EBP expression and the innate immune system.  Another study 
has also highlighted the role of TRPM2 in positively regulating CXCL8 production 
leading to increased tissue damage at sites of inflammation when compared to TRPM2-
defficient mice 54.  Another potential pathway to cell death and excessive tissue damage 
could be a result of the accumulation on intracellular iron (FE2+) which has been shown 
to sensitize TRPM2 channels resulting in an upregulation of CXCL8 production 149.  
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Differential gene expression analyses 
The first analysis using compared the samples based on a horse’s phenotypic 
classification when it was a foal.  This was done to identify any potential changes in 
expression that occurred as a result of disease status while foals.  This did not appear to 
be the case as there was no evidence that disease status as a foal had any effect on 
expression as an adult horse.  The transcriptome-wide analysis using both edgeR and 
cuffdiff did not reveal any concordant results.  This may be attributable to several factors.  
Each program uses a different method to predict differentially expressed genes and each 
is tailored to conduct different types of analysis.  Cuffdiff uses a mixture of distributions 
to account for the uncertainty in mapping a read and the variability in read count while 
edgeR primarily focuses on the variability in read count across replicates 84,141.  The 
results from edgeR appear to be more conservative in our experiment as only 3 genes 
were identified as differentially expressed in comparison to cuffdiff which identified 58 
genes.  There is also evidence to suggest that edgeR is not always a more conservative 
approach; thus, the observed discrepancy might reflect some other biological or 
technical property present in the data but no other metrics suggest this to be the case 150.  
Also, cuffdiff uses the accepted_hits.bam files and a gene annotation file to calculate 
differential expression.  This removes the HTSeq count step and might have contributed 
to the differing results.  In an effort to maximize the inferences drawn from our data, we 
elected to use the genes identified by cuffdiff to better leverage our data in elucidating 
biological pathways and processes playing a role in susceptibility to R. equi pneumonia. 
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There are several other factors to consider regarding RNA-Seq and the outcome of its 
analysis.  RNA-Seq reflects steady state levels of RNA which encompasses the rate of 
transcription, rate of degradation, post-transcriptional phases, and post-translational 
modifications 151.  For example, a 1.3-fold increase in expression of C/EBP within the 
AA genotypes group over the non-AA genotypes is a complex finding, as it is in any 
case investigating differentially expressed genes.  A first step in following up on the 
findings and better understanding this gene and pathway as it relates to R. equi 
pneumonia would be to confirm the RNA expressions levels by another method.  Also, 
we do not know if a 1.3-fold increase in RNA correlates and indicates a 1.3 fold increase 
in the protein level of C/EBP in these horses.  A recent study found that on average only 
40% of the variability in protein levels of the cell could be explained by mRNA levels 
152.  This finding shows the dynamic processes of transcription and translation cannot be 
easily generalized as to their functional implications.   
 
Limitations 
One limitation of this study is that it was conducted in mature horses and not in foals: 
gene expression as adults may not reflect the gene expression of these horses as foals 
when they were susceptible to R. equi; however, the marker genotypes will not have 
changed (i.e., AA, AB, BB) and therefore their impact on functional transcription should 
remain the same.  To ensure that clinical status as a foal was not impacting differential 
gene expression an adult, we used their respective phenotypic classifier as foals to group 
them for a differential expression analysis.  A second limitation is that the region of 
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interest’s involvement with and relationship to R. equi infection may be of a tissue-
specific nature (e.g., in the lung or in alveolar macrophages) and thus not captured or 
accurately reflected by RNA-Seq data from whole blood.  A third limitation is the small 
sample size of the study but note that our sample size is dictated by funding.  Previous 
studies have yielded important results using fewer horses and these presently reported 
results should be considered relevant to the understanding of susceptibility to R. equi  
86,87,94.  Despite these limitations, we believe the results and contribution to knowledge of 
this disease outweigh these limitations. 
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CHAPTER IV 
CONCLUSIONS 
 
Genetic evidence regarding foal susceptibility to R. equi pneumonia is very clear in its 
common theme of implicating innate immune responses.  It is certainly the case that 
susceptibility to R. equi pneumonia is controlled not by one, but by many genes within 
the horse and it is important to consider all findings regarding R.equi together when 
drawing conclusions.  The findings presented here further strengthen that theme as 
concordant results were also found.  The literature, which has been reviewed and 
presented here, agrees with the findings of this work.  The first studies identifying genes 
associated with R. equi pneumonia were candidate gene studies and predominantly 
conducted using the Thoroughbred breed.  Although the same associations were not 
made within the analysis of these data sets, overall themes of innate immunity genes and 
pathways were identified.  This is an important finding as this work was conducted in 
Quarter horses.  Generating supporting evidence across multiple breeds is important and 
highly compelling evidence that foal susceptibility to R.equi pneumonia is regulated 
through innate immune pathways.  The importance of neutrophil function and signaling 
was a common theme found by these analyses.   
This research also generated new hypothesis that will require further attention to identify 
the role of genetic variation in susceptibility to R. equi pneumonia.  Confirmation of the 
isoform expression at the TRPM2 locus as well as further evidence supporting the gene 
model will be required.  The evidence presented in the human literature warrants further 
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investigation of this possibility in the horse as well.  Findings that are generated by 
future studies will be essential steps in identifying therapeutic targets and aiding in the 
discovery of novel treatments for R. equi pneumonia.    
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APPENDIX 2.1 
 
 
Supplementary Table 2.1.  CNV regions called from foals across all phenotypic groups 
during CNV association analysis. 
 
Comparison 1   Comparison 2   Comparison 3  
CNV 1 test  CNV2 test  CNV3 test 
CNVR_1261 0.019173035  CNVR_0753 0.01013  CNVR_1354 0.010975 
CNVR_1936 0.026441799  CNVR_0873 0.012085  CNVR_0458 0.026079 
CNVR_0645 0.030323779  CNVR_1936 0.032181  CNVR_0645 0.029019 
CNVR_1354 0.036282715  CNVR_0391 0.032609  CNVR_1483 0.039921 
CNVR_0873 0.054436922  CNVR_0179 0.03349  CNVR_1253 0.04016 
CNVR_1483 0.0593947  CNVR_1261 0.033965  CNVR_1815 0.041391 
CNVR_0753 0.065976784  CNVR_1905 0.048269  CNVR_1237 0.048842 
CNVR_1457 0.066759568  CNVR_0868 0.061215  CNVR_0777 0.049978 
CNVR_1166 0.071559078  CNVR_1084 0.062855  CNVR_0841 0.053025 
CNVR_1815 0.079049058  CNVR_1148 0.064187  CNVR_1457 0.054011 
CNVR_1074 0.084420521  CNVR_1074 0.087307  CNVR_0881 0.060429 
CNVR_0868 0.102610495  CNVR_0090 0.088076  CNVR_2115 0.063301 
CNVR_1237 0.106753947  CNVR_1190 0.088206  CNVR_0112 0.063932 
CNVR_1122 0.112387847  CNVR_0643 0.091409  CNVR_1909 0.069793 
CNVR_0391 0.117231864  CNVR_1189 0.09713  CNVR_1936 0.074018 
CNVR_1293 0.121555531  CNVR_0915 0.10311  CNVR_0137 0.074887 
CNVR_1905 0.122032064  CNVR_0708 0.108013  CNVR_1293 0.078871 
CNVR_0773 0.130179977  CNVR_0890 0.10838  CNVR_1261 0.081324 
CNVR_0458 0.130778784  CNVR_0218 0.110601  CNVR_1930 0.082416 
CNVR_2115 0.131219107  CNVR_0465 0.110615  CNVR_1166 0.084361 
CNVR_1097 0.135570469  CNVR_1900 0.110871  CNVR_0008 0.087838 
CNVR_1253 0.136510275  CNVR_1458 0.111695  CNVR_2174 0.089134 
CNVR_0008 0.139943975  CNVR_0463 0.123782  CNVR_1555 0.092809 
CNVR_1418 0.15767926  CNVR_0525 0.126266  CNVR_1198 0.094162 
CNVR_2221 0.160157153  CNVR_1081 0.128234  CNVR_1513 0.098585 
CNVR_0643 0.188492653  CNVR_0645 0.128611  CNVR_1971 0.111661 
CNVR_1678 0.193745367  CNVR_0094 0.129254  CNVR_0309 0.11343 
CNVR_1190 0.194601997  CNVR_1881 0.135123  CNVR_1841 0.114328 
CNVR_0890 0.195951154  CNVR_0743 0.135193  CNVR_1662 0.119684 
CNVR_0915 0.204958444  CNVR_1122 0.135547  CNVR_1097 0.12376 
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CNVR_0525 0.212064567  CNVR_0742 0.139554  CNVR_1274 0.140899 
CNVR_0635 0.225165786  CNVR_1764 0.139793  CNVR_1826 0.149904 
CNVR_1915 0.230353666  CNVR_0939 0.14053  CNVR_0269 0.15104 
CNVR_1900 0.237406365  CNVR_1786 0.146216  CNVR_0322 0.153913 
CNVR_0881 0.237700852  CNVR_0664 0.1475  CNVR_2234 0.15885 
CNVR_0076 0.239895885  CNVR_0949 0.149696  CNVR_2107 0.161239 
CNVR_1473 0.255928454  CNVR_1027 0.153132  CNVR_2237 0.162794 
CNVR_1909 0.262603785  CNVR_0056 0.156166  CNVR_0088 0.163527 
CNVR_0708 0.264237205  CNVR_0773 0.158931  CNVR_0076 0.164981 
CNVR_1874 0.270338275  CNVR_0212 0.160537  CNVR_1328 0.171146 
CNVR_0237 0.276379102  CNVR_1721 0.165236  CNVR_1383 0.173899 
CNVR_1148 0.278418665  CNVR_1345 0.168864  CNVR_1268 0.177435 
CNVR_1455 0.287915853  CNVR_2051 0.176407  CNVR_1260 0.178015 
CNVR_0842 0.294342951  CNVR_2234 0.176412  CNVR_1074 0.178281 
CNVR_0664 0.296260331  CNVR_1166 0.179104  CNVR_0154 0.182245 
CNVR_0606 0.300079787  CNVR_1483 0.181291  CNVR_0409 0.184381 
CNVR_0593 0.300656968  CNVR_1095 0.181427  CNVR_2011 0.184488 
CNVR_1474 0.301525745  CNVR_1457 0.182906  CNVR_1636 0.187221 
CNVR_0094 0.306255913  CNVR_1355 0.185885  CNVR_1084 0.187467 
CNVR_1351 0.306754219  CNVR_0295 0.189518  CNVR_0006 0.192393 
CNVR_0939 0.307035028  CNVR_0993 0.192112  CNVR_1859 0.199032 
CNVR_1841 0.308594592  CNVR_1700 0.192922  CNVR_0217 0.199663 
CNVR_2127 0.308704165  CNVR_0128 0.194288  CNVR_2145 0.200479 
CNVR_0847 0.312907485  CNVR_1787 0.196726  CNVR_0785 0.200527 
CNVR_2149 0.317208702  CNVR_1870 0.196915  CNVR_1956 0.200651 
CNVR_0137 0.320305357  CNVR_0735 0.199355  CNVR_2059 0.213569 
CNVR_1813 0.326881751  CNVR_1066 0.200972  CNVR_0814 0.219067 
CNVR_1833 0.33054393  CNVR_0321 0.201898  CNVR_2083 0.222987 
CNVR_1002 0.335267606  CNVR_0816 0.202033  CNVR_1263 0.230647 
CNVR_1555 0.339863597  CNVR_1214 0.202204  CNVR_2118 0.238848 
CNVR_1278 0.341389981  CNVR_2243 0.203174  CNVR_1122 0.244064 
CNVR_0993 0.34256069  CNVR_2152 0.203279  CNVR_0847 0.247441 
CNVR_2107 0.3430277  CNVR_1874 0.205366  CNVR_0169 0.249155 
CNVR_1027 0.346081794  CNVR_1085 0.207509  CNVR_1678 0.252626 
CNVR_0169 0.347238742  CNVR_1002 0.21149  CNVR_2232 0.25493 
CNVR_1458 0.352084477  CNVR_1418 0.214819  CNVR_0250 0.255496 
CNVR_1965 0.35355713  CNVR_1678 0.21793  CNVR_0465 0.256833 
CNVR_0218 0.355955648  CNVR_1726 0.219095  CNVR_2221 0.261694 
CNVR_1342 0.356569729  CNVR_0412 0.223336  CNVR_1187 0.26419 
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CNVR_1066 0.356592914  CNVR_2221 0.225817  CNVR_2069 0.266439 
CNVR_1513 0.356685244  CNVR_0635 0.22785  CNVR_2149 0.273412 
CNVR_1198 0.356924669  CNVR_2089 0.228299  CNVR_1255 0.276083 
CNVR_1636 0.357772891  CNVR_1702 0.229675  CNVR_0050 0.279331 
CNVR_0322 0.358083053  CNVR_0632 0.229686  CNVR_2251 0.281156 
CNVR_1255 0.367908607  CNVR_1407 0.22993  CNVR_1486 0.28153 
CNVR_1894 0.372358443  CNVR_1859 0.230183  CNVR_1455 0.283633 
CNVR_2145 0.373049752  CNVR_2054 0.231243  CNVR_2165 0.284531 
CNVR_0777 0.373239288  CNVR_0794 0.2333  CNVR_1418 0.284891 
CNVR_1268 0.374495457  CNVR_1915 0.233724  CNVR_0639 0.287119 
CNVR_1260 0.375543669  CNVR_0462 0.233882  CNVR_0162 0.287996 
CNVR_0154 0.378018236  CNVR_0536 0.234475  CNVR_0842 0.28943 
CNVR_1061 0.380491293  CNVR_1278 0.235895  CNVR_0773 0.289497 
CNVR_0162 0.381586642  CNVR_0894 0.236604  CNVR_2072 0.290513 
CNVR_0248 0.384163351  CNVR_1246 0.238735  CNVR_1764 0.295355 
CNVR_0417 0.385116228  CNVR_0785 0.239357  CNVR_2127 0.296268 
CNVR_2118 0.386096841  CNVR_0558 0.239998  CNVR_1061 0.298337 
CNVR_0949 0.386236353  CNVR_0637 0.241343  CNVR_0160 0.299678 
CNVR_1446 0.386628181  CNVR_0738 0.24247  CNVR_2024 0.301934 
CNVR_0295 0.392734284  CNVR_2165 0.24604  CNVR_1013 0.304986 
CNVR_0841 0.393175609  CNVR_1473 0.246956  CNVR_1624 0.306462 
CNVR_0056 0.393370481  CNVR_1317 0.256478  CNVR_1277 0.31006 
CNVR_2181 0.395955599  CNVR_1077 0.257444  CNVR_1216 0.312502 
CNVR_1623 0.397998194  CNVR_1144 0.258629  CNVR_0251 0.319321 
CNVR_0463 0.398650794  CNVR_1640 0.258957  CNVR_0689 0.326737 
CNVR_1700 0.400488587  CNVR_1838 0.264326  CNVR_0482 0.328061 
CNVR_1826 0.402151008  CNVR_1304 0.265933  CNVR_2213 0.329374 
CNVR_1355 0.406264293  CNVR_0722 0.266088  CNVR_2246 0.329672 
CNVR_1752 0.408495979  CNVR_1097 0.26761  CNVR_1652 0.335554 
CNVR_1400 0.412139219  CNVR_0606 0.267653  CNVR_0610 0.335554 
CNVR_0894 0.419382529  CNVR_1138 0.270273  CNVR_0052 0.340177 
CNVR_0128 0.423224248  CNVR_2128 0.272155  CNVR_0237 0.341367 
CNVR_2015 0.430757448  CNVR_1107 0.272545  CNVR_1308 0.342132 
CNVR_1956 0.436675211  CNVR_1813 0.272887  CNVR_0593 0.343487 
CNVR_0462 0.437983353  CNVR_1370 0.2766  CNVR_1577 0.34689 
CNVR_1246 0.440989021  CNVR_1188 0.277599  CNVR_0873 0.346904 
CNVR_1039 0.442068868  CNVR_1469 0.277633  CNVR_2181 0.349781 
CNVR_0558 0.448196739  CNVR_1023 0.278379  CNVR_0179 0.350252 
CNVR_1693 0.452186739  CNVR_0331 0.27927  CNVR_1272 0.35201 
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CNVR_1680 0.455263752  CNVR_2015 0.281794  CNVR_1085 0.353449 
CNVR_1662 0.458555504  CNVR_2009 0.286619  CNVR_1693 0.356704 
CNVR_1786 0.459389915  CNVR_1926 0.28678  CNVR_1642 0.357768 
CNVR_0742 0.460382863  CNVR_1474 0.286833  CNVR_2175 0.359971 
CNVR_1214 0.462444812  CNVR_1015 0.28734  CNVR_1825 0.367001 
CNVR_0217 0.467192905  CNVR_0063 0.291507  CNVR_2262 0.370763 
CNVR_0876 0.467295248  CNVR_0052 0.291649  CNVR_1167 0.373317 
CNVR_1721 0.468517458  CNVR_1885 0.292599  CNVR_2030 0.373893 
CNVR_1725 0.468737315  CNVR_0084 0.292785  CNVR_1891 0.37424 
CNVR_0743 0.470975233  CNVR_0493 0.293246  CNVR_0456 0.377432 
CNVR_1971 0.474121677  CNVR_0245 0.293608  CNVR_1351 0.385905 
CNVR_0589 0.481494511  CNVR_1446 0.295415  CNVR_0849 0.387034 
CNVR_1081 0.485372036  CNVR_1634 0.29689  CNVR_2239 0.387278 
CNVR_1759 0.488655354  CNVR_1930 0.301234  CNVR_2200 0.388868 
CNVR_1138 0.489468285  CNVR_2157 0.303455  CNVR_1039 0.390115 
CNVR_0212 0.491676969  CNVR_2060 0.304606  CNVR_0216 0.391 
CNVR_0816 0.492042257  CNVR_1830 0.308676  CNVR_1189 0.396292 
CNVR_1870 0.49275206  CNVR_1532 0.308718  CNVR_2148 0.397451 
CNVR_1345 0.492964883  CNVR_1785 0.312669  CNVR_1915 0.39843 
CNVR_0493 0.493153277  CNVR_1185 0.313966  CNVR_1879 0.398643 
CNVR_0179 0.493267691  CNVR_1570 0.315686  CNVR_1914 0.404673 
CNVR_1532 0.495719888  CNVR_0814 0.317145  CNVR_0895 0.410258 
CNVR_0090 0.497165008  CNVR_1815 0.317497  CNVR_0875 0.410296 
CNVR_0905 0.499536659  CNVR_1328 0.32428  CNVR_1058 0.410509 
CNVR_1881 0.502510476  CNVR_0281 0.324424  CNVR_2060 0.414612 
CNVR_0245 0.506490746  CNVR_1383 0.324587  CNVR_0660 0.420235 
CNVR_0106 0.515021679  CNVR_0905 0.329067  CNVR_0432 0.420244 
CNVR_1185 0.515283499  CNVR_1256 0.329664  CNVR_0876 0.42095 
CNVR_0084 0.515403738  CNVR_1988 0.330455  CNVR_1894 0.421573 
CNVR_0269 0.515973621  CNVR_1624 0.333282  CNVR_0632 0.424844 
CNVR_0010 0.517166067  CNVR_1400 0.333663  CNVR_1965 0.427686 
CNVR_0309 0.521057179  CNVR_0417 0.337177  CNVR_0570 0.432284 
CNVR_1407 0.52288646  CNVR_0885 0.337254  CNVR_1833 0.432463 
CNVR_1921 0.523378684  CNVR_1921 0.337919  CNVR_0395 0.434913 
CNVR_0875 0.523696262  CNVR_0554 0.338002  CNVR_0940 0.435843 
CNVR_0216 0.525320715  CNVR_2098 0.338084  CNVR_2038 0.435921 
CNVR_1633 0.528643404  CNVR_2241 0.338883  CNVR_0149 0.437174 
CNVR_0734 0.532066367  CNVR_1623 0.34014  CNVR_2089 0.440611 
CNVR_0689 0.53912549  CNVR_1715 0.340467  CNVR_1473 0.443917 
 94 
 
Supp. Tbl. 2.1. Continued        
CNVR_2152 0.542562558  CNVR_1833 0.340595  CNVR_1983 0.447395 
CNVR_0063 0.54337445  CNVR_1611 0.34109  CNVR_1359 0.448745 
CNVR_0149 0.543929363  CNVR_1342 0.341118  CNVR_1107 0.448907 
CNVR_0637 0.544554965  CNVR_1759 0.341574  CNVR_0635 0.45229 
CNVR_1988 0.545450591  CNVR_0547 0.341976  CNVR_0868 0.452618 
CNVR_1274 0.546548081  CNVR_2194 0.342179  CNVR_1832 0.452837 
CNVR_1095 0.546646775  CNVR_0237 0.342785  CNVR_1752 0.456635 
CNVR_2054 0.549154429  CNVR_1222 0.343497  CNVR_1787 0.459803 
CNVR_1077 0.550851809  CNVR_0010 0.344484  CNVR_0571 0.463383 
CNVR_1370 0.552403756  CNVR_0620 0.345165  CNVR_1707 0.476333 
CNVR_0735 0.552852954  CNVR_1351 0.346592  CNVR_1108 0.479237 
CNVR_1047 0.560036206  CNVR_0746 0.350347  CNVR_1633 0.486882 
CNVR_1187 0.563847152  CNVR_0409 0.354334  CNVR_1533 0.487726 
CNVR_2102 0.566307761  CNVR_0965 0.35586  CNVR_0470 0.489644 
CNVR_0112 0.566973515  CNVR_1725 0.358387  CNVR_1342 0.489856 
CNVR_0321 0.574370336  CNVR_2264 0.358461  CNVR_0919 0.492929 
CNVR_1188 0.57639788  CNVR_2090 0.358646  CNVR_1119 0.494754 
CNVR_1726 0.580114693  CNVR_0660 0.361515  CNVR_0224 0.496761 
CNVR_2174 0.582134018  CNVR_0610 0.362367  CNVR_0106 0.497812 
CNVR_0536 0.586055988  CNVR_1293 0.363347  CNVR_1222 0.499582 
CNVR_1838 0.590667282  CNVR_0593 0.363659  CNVR_1304 0.503541 
CNVR_1990 0.59183767  CNVR_1829 0.364313  CNVR_0331 0.504547 
CNVR_1930 0.591920252  CNVR_0663 0.366271  CNVR_1474 0.507492 
CNVR_1640 0.594874442  CNVR_1233 0.368664  CNVR_1905 0.507823 
CNVR_2051 0.595796923  CNVR_0251 0.368894  CNVR_0320 0.510656 
CNVR_0885 0.597868322  CNVR_0571 0.369361  CNVR_0915 0.5109 
CNVR_1820 0.59940217  CNVR_0248 0.369512  CNVR_1647 0.511797 
CNVR_1013 0.602877082  CNVR_1954 0.371435  CNVR_1317 0.512858 
CNVR_1829 0.603593319  CNVR_0125 0.372098  CNVR_1935 0.515449 
CNVR_1203 0.606896359  CNVR_0956 0.372415  CNVR_0606 0.51688 
CNVR_0232 0.607271064  CNVR_1533 0.379195  CNVR_1444 0.517524 
CNVR_0006 0.608303438  CNVR_0008 0.383717  CNVR_0502 0.518799 
CNVR_1647 0.611329121  CNVR_1990 0.384717  CNVR_1144 0.521745 
CNVR_1233 0.611657908  CNVR_0968 0.38813  CNVR_0090 0.52249 
CNVR_1189 0.612282582  CNVR_1972 0.389229  CNVR_1203 0.52422 
CNVR_1469 0.612987289  CNVR_0585 0.389352  CNVR_1972 0.525088 
CNVR_2210 0.613191851  CNVR_1680 0.391567  CNVR_2090 0.525193 
CNVR_0956 0.61596022  CNVR_1690 0.394229  CNVR_1340 0.537771 
CNVR_0794 0.616538033  CNVR_2174 0.395206  CNVR_2245 0.540141 
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CNVR_1570 0.619367966  CNVR_0385 0.405193  CNVR_2103 0.542406 
CNVR_0738 0.62107015  CNVR_2071 0.406967  CNVR_2202 0.542557 
CNVR_0250 0.622889942  CNVR_0748 0.408374  CNVR_1821 0.542625 
CNVR_2059 0.624850971  CNVR_0821 0.408958  CNVR_0075 0.544846 
CNVR_1702 0.627319642  CNVR_2072 0.408982  CNVR_1813 0.546327 
CNVR_2237 0.627567086  CNVR_1047 0.411082  CNVR_0643 0.547823 
CNVR_1023 0.630124004  CNVR_0895 0.41109  CNVR_2009 0.548626 
CNVR_0852 0.630878527  CNVR_0470 0.411409  CNVR_0525 0.553185 
CNVR_2243 0.632486122  CNVR_1354 0.412799  CNVR_1874 0.555976 
CNVR_0908 0.635212908  CNVR_1161 0.412821  CNVR_1634 0.559665 
CNVR_0125 0.63527982  CNVR_1263 0.413166  CNVR_1978 0.561392 
CNVR_2232 0.637466332  CNVR_1167 0.415639  CNVR_0248 0.564226 
CNVR_1088 0.638944176  CNVR_1978 0.417512  CNVR_0616 0.564886 
CNVR_0221 0.645103991  CNVR_1652 0.418163  CNVR_2098 0.567012 
CNVR_0034 0.646259493  CNVR_0940 0.424137  CNVR_0412 0.567729 
CNVR_2200 0.647394944  CNVR_1340 0.426668  CNVR_1164 0.567984 
CNVR_2024 0.647723764  CNVR_1455 0.426749  CNVR_1836 0.569905 
CNVR_0570 0.648628347  CNVR_2039 0.42774  CNVR_0189 0.573111 
CNVR_0651 0.654081531  CNVR_0194 0.429715  CNVR_0281 0.57434 
CNVR_1272 0.658196394  CNVR_0421 0.43189  CNVR_0890 0.574972 
CNVR_0200 0.66107243  CNVR_2102 0.433798  CNVR_0145 0.57653 
CNVR_1086 0.664093396  CNVR_0320 0.437989  CNVR_0722 0.576747 
CNVR_2148 0.667319808  CNVR_0112 0.438181  CNVR_1611 0.579142 
CNVR_1926 0.669018095  CNVR_0734 0.439008  CNVR_2071 0.58118 
CNVR_0965 0.672905051  CNVR_0842 0.439343  CNVR_1783 0.582476 
CNVR_1368 0.678221034  CNVR_0919 0.443136  CNVR_0107 0.582519 
CNVR_1891 0.679591513  CNVR_1308 0.444706  CNVR_1885 0.582701 
CNVR_1764 0.680452056  CNVR_0764 0.455049  CNVR_1161 0.585511 
CNVR_1715 0.680456207  CNVR_1965 0.457717  CNVR_2194 0.586724 
CNVR_0145 0.681782642  CNVR_0107 0.457998  CNVR_2039 0.588615 
CNVR_1830 0.683626035  CNVR_1914 0.45813  CNVR_0385 0.594324 
CNVR_1690 0.683900491  CNVR_0364 0.458269  CNVR_2051 0.604225 
CNVR_1256 0.686665985  CNVR_1820 0.461279  CNVR_0620 0.605812 
CNVR_1787 0.689945643  CNVR_1758 0.463878  CNVR_0554 0.610336 
CNVR_2128 0.6900729  CNVR_0073 0.464786  CNVR_0547 0.612881 
CNVR_1015 0.692257865  CNVR_1237 0.465354  CNVR_1081 0.617642 
CNVR_0722 0.692819991  CNVR_1983 0.4655  CNVR_1881 0.618619 
CNVR_2213 0.693279729  CNVR_2127 0.466021  CNVR_1954 0.620539 
CNVR_2241 0.702703417  CNVR_1935 0.467551  CNVR_1307 0.623591 
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CNVR_1090 0.703726175  CNVR_0088 0.469512  CNVR_0746 0.625403 
CNVR_1785 0.70377787  CNVR_2011 0.471537  CNVR_1278 0.626328 
CNVR_0830 0.708114532  CNVR_0589 0.47521  CNVR_2128 0.628047 
CNVR_0465 0.709176128  CNVR_1090 0.475641  CNVR_1190 0.629977 
CNVR_0050 0.710384752  CNVR_1752 0.47929  CNVR_0218 0.630354 
CNVR_0412 0.711518528  CNVR_2115 0.479351  CNVR_1446 0.631367 
CNVR_0512 0.712423247  CNVR_0177 0.483933  CNVR_2124 0.631534 
CNVR_0088 0.717514252  CNVR_0512 0.484098  CNVR_0118 0.633582 
CNVR_1821 0.720149061  CNVR_2030 0.485205  CNVR_2264 0.636648 
CNVR_2089 0.720664021  CNVR_0777 0.48825  CNVR_0498 0.639549 
CNVR_1502 0.725717078  CNVR_1486 0.492776  CNVR_1400 0.641061 
CNVR_1108 0.726162433  CNVR_0076 0.493369  CNVR_0738 0.64379 
CNVR_2175 0.727457672  CNVR_1894 0.50116  CNVR_0221 0.644139 
CNVR_1313 0.728959652  CNVR_1088 0.501313  CNVR_0589 0.647401 
CNVR_1599 0.732251546  CNVR_1374 0.507223  CNVR_0200 0.647748 
CNVR_1670 0.734643008  CNVR_1577 0.508919  CNVR_1730 0.648753 
CNVR_1295 0.740467945  CNVR_0616 0.509964  CNVR_2243 0.650076 
CNVR_2103 0.740470386  CNVR_1502 0.510507  CNVR_1121 0.654754 
CNVR_0219 0.740588861  CNVR_2119 0.512446  CNVR_1623 0.656464 
CNVR_1634 0.741710877  CNVR_1121 0.51377  CNVR_2157 0.6571 
CNVR_0968 0.742092407  CNVR_0034 0.519698  CNVR_0417 0.665303 
CNVR_1885 0.74264059  CNVR_1730 0.519963  CNVR_0761 0.665862 
CNVR_2157 0.743628137  CNVR_2237 0.522139  CNVR_0261 0.666494 
CNVR_1317 0.743729161  CNVR_2149 0.526759  CNVR_0247 0.670066 
CNVR_0096 0.74443516  CNVR_0502 0.530001  CNVR_0585 0.671027 
CNVR_1304 0.745468538  CNVR_2251 0.535253  CNVR_1854 0.671485 
CNVR_0160 0.748673658  CNVR_0224 0.535458  CNVR_2143 0.671706 
CNVR_0554 0.753315241  CNVR_1436 0.536501  CNVR_1015 0.672078 
CNVR_0911 0.753771217  CNVR_0232 0.54003  CNVR_0019 0.674882 
CNVR_0663 0.755824136  CNVR_0456 0.542542  CNVR_0748 0.676858 
CNVR_2264 0.755924637  CNVR_2069 0.542648  CNVR_1670 0.677716 
CNVR_1568 0.756685645  CNVR_1030 0.545439  CNVR_1614 0.679536 
CNVR_0177 0.759656853  CNVR_1444 0.54555  CNVR_2241 0.680388 
CNVR_2083 0.759738011  CNVR_1216 0.546338  CNVR_1926 0.68398 
CNVR_1156 0.762633159  CNVR_1599 0.549044  CNVR_1680 0.685373 
CNVR_0547 0.763997678  CNVR_1736 0.550393  CNVR_0663 0.68568 
CNVR_2011 0.768523777  CNVR_2210 0.550905  CNVR_1785 0.687382 
CNVR_0281 0.768773981  CNVR_2083 0.555595  CNVR_0165 0.687468 
CNVR_0421 0.769677558  CNVR_1836 0.558651  CNVR_0391 0.689027 
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CNVR_1263 0.769703931  CNVR_2124 0.55918  CNVR_0821 0.690771 
CNVR_1144 0.771909705  CNVR_1277 0.559302  CNVR_0364 0.697859 
CNVR_0585 0.773739452  CNVR_0096 0.571865  CNVR_0194 0.698594 
CNVR_2239 0.774280573  CNVR_0482 0.574268  CNVR_0734 0.703274 
CNVR_1328 0.775490316  CNVR_0639 0.574839  CNVR_1313 0.706645 
CNVR_1832 0.776302994  CNVR_0847 0.576804  CNVR_0735 0.707859 
CNVR_1954 0.777671262  CNVR_1039 0.57681  CNVR_1023 0.710084 
CNVR_1825 0.780678122  CNVR_0123 0.582182  CNVR_0968 0.710716 
CNVR_0331 0.781936404  CNVR_0852 0.587895  CNVR_1374 0.710992 
CNVR_0764 0.785159295  CNVR_1642 0.58939  CNVR_0421 0.71383 
CNVR_0748 0.785689097  CNVR_1061 0.59097  CNVR_1726 0.716561 
CNVR_2194 0.786341428  CNVR_1879 0.591476  CNVR_0212 0.719077 
CNVR_1107 0.786440929  CNVR_0651 0.596852  CNVR_1130 0.729108 
CNVR_0194 0.789486969  CNVR_2246 0.598963  CNVR_0908 0.729848 
CNVR_1611 0.791505771  CNVR_2181 0.601334  CNVR_1786 0.7345 
CNVR_2069 0.792605485  CNVR_1253 0.605718  CNVR_1256 0.737128 
CNVR_2262 0.792949313  CNVR_2202 0.605898  CNVR_0536 0.74188 
CNVR_2098 0.800839219  CNVR_0395 0.611426  CNVR_2152 0.745636 
CNVR_2245 0.801535546  CNVR_0164 0.611436  CNVR_0742 0.746492 
CNVR_1030 0.803568577  CNVR_1974 0.612761  CNVR_1568 0.747303 
CNVR_0821 0.803595921  CNVR_1086 0.619782  CNVR_1095 0.749169 
CNVR_1758 0.803728576  CNVR_0432 0.631866  CNVR_0911 0.749826 
CNVR_2009 0.807544903  CNVR_1255 0.633369  CNVR_1002 0.749883 
CNVR_1084 0.807902202  CNVR_1058 0.634475  CNVR_0321 0.750669 
CNVR_0620 0.807928187  CNVR_0106 0.638502  CNVR_1715 0.750715 
CNVR_2038 0.811631272  CNVR_2059 0.641257  CNVR_1592 0.751062 
CNVR_0073 0.811658531  CNVR_1368 0.644378  CNVR_0073 0.751348 
CNVR_0632 0.81211763  CNVR_1707 0.646114  CNVR_1830 0.751824 
CNVR_0247 0.812733136  CNVR_0876 0.648167  CNVR_1758 0.754617 
CNVR_1374 0.813280675  CNVR_0849 0.652087  CNVR_0018 0.754725 
CNVR_0075 0.813750246  CNVR_0908 0.654305  CNVR_0764 0.757955 
CNVR_1436 0.820908094  CNVR_0006 0.654853  CNVR_1974 0.758772 
CNVR_0123 0.822410239  CNVR_0841 0.655251  CNVR_2119 0.75992 
CNVR_1307 0.823115212  CNVR_0162 0.655554  CNVR_0664 0.76058 
CNVR_2246 0.82358608  CNVR_0169 0.655608  CNVR_0219 0.761777 
CNVR_2060 0.825295236  CNVR_0830 0.656211  CNVR_1736 0.766852 
CNVR_0482 0.828303296  CNVR_0223 0.657222  CNVR_0794 0.773283 
CNVR_0165 0.829246198  CNVR_0160 0.657222  CNVR_1368 0.773898 
CNVR_1972 0.830200343  CNVR_0498 0.658321  CNVR_1436 0.782388 
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CNVR_0849 0.830670313  CNVR_1119 0.659159  CNVR_0753 0.782575 
CNVR_1216 0.830810695  CNVR_1295 0.660104  CNVR_2054 0.785555 
CNVR_0385 0.831753372  CNVR_2239 0.66423  CNVR_0232 0.785715 
CNVR_0409 0.833012392  CNVR_0189 0.664232  CNVR_1721 0.786255 
CNVR_1222 0.833746396  CNVR_0309 0.666138  CNVR_1640 0.788451 
CNVR_2119 0.835211044  CNVR_0458 0.666777  CNVR_0965 0.788659 
CNVR_1788 0.836523964  CNVR_0261 0.670203  CNVR_1725 0.789488 
CNVR_2090 0.838188376  CNVR_2175 0.670221  CNVR_1494 0.793054 
CNVR_0164 0.838951718  CNVR_1156 0.67066  CNVR_0184 0.79447 
CNVR_0761 0.839611968  CNVR_1582 0.678136  CNVR_0993 0.795518 
CNVR_1315 0.839836322  CNVR_1825 0.684651  CNVR_0852 0.795803 
CNVR_1161 0.841491256  CNVR_1359 0.685699  CNVR_1759 0.797956 
CNVR_0548 0.843256488  CNVR_1693 0.696551  CNVR_1066 0.799407 
CNVR_2014 0.84504204  CNVR_1164 0.699012  CNVR_0223 0.800925 
CNVR_2039 0.845746401  CNVR_1783 0.699531  CNVR_1407 0.804828 
CNVR_0364 0.847597677  CNVR_1315 0.70032  CNVR_2015 0.807381 
CNVR_2251 0.847667486  CNVR_1274 0.704294  CNVR_1469 0.807715 
CNVR_1978 0.849244871  CNVR_2262 0.70472  CNVR_1086 0.809959 
CNVR_0746 0.854128102  CNVR_1633 0.712672  CNVR_1656 0.814001 
CNVR_2072 0.861064022  CNVR_0118 0.718098  CNVR_1345 0.824746 
CNVR_1642 0.862326746  CNVR_0881 0.718891  CNVR_0743 0.828016 
CNVR_0184 0.862821977  CNVR_1854 0.721223  CNVR_0939 0.828538 
CNVR_1736 0.863236829  CNVR_1614 0.726644  CNVR_0651 0.831605 
CNVR_0019 0.867188778  CNVR_1343 0.72893  CNVR_0463 0.834344 
CNVR_0814 0.868601023  CNVR_0154 0.734868  CNVR_0830 0.837126 
CNVR_2165 0.869228407  CNVR_0200 0.737917  CNVR_0123 0.841104 
CNVR_0432 0.870978621  CNVR_2038 0.738384  CNVR_1870 0.84119 
CNVR_1359 0.871008784  CNVR_1832 0.738834  CNVR_1570 0.842856 
CNVR_1486 0.871584689  CNVR_1909 0.744698  CNVR_1702 0.843347 
CNVR_1085 0.872417313  CNVR_2118 0.74577  CNVR_2210 0.844328 
CNVR_2234 0.874931207  CNVR_0221 0.749298  CNVR_1395 0.849025 
CNVR_0018 0.879382934  CNVR_0050 0.749406  CNVR_1690 0.853128 
CNVR_0660 0.879390182  CNVR_1788 0.753043  CNVR_2102 0.854766 
CNVR_2071 0.88026757  CNVR_0250 0.755217  CNVR_0177 0.855424 
CNVR_1340 0.88369463  CNVR_1494 0.758818  CNVR_2047 0.855548 
CNVR_0456 0.88621487  CNVR_1260 0.765639  CNVR_1838 0.856103 
CNVR_0395 0.88703783  CNVR_2143 0.768073  CNVR_1027 0.858799 
CNVR_1383 0.88736818  CNVR_2213 0.771685  CNVR_0637 0.863866 
CNVR_1879 0.88862702  CNVR_2232 0.776606  CNVR_0164 0.864131 
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CNVR_0107 0.889018782  CNVR_2107 0.777316  CNVR_0531 0.869072 
CNVR_0223 0.890253115  CNVR_1647 0.7803  CNVR_0894 0.872476 
CNVR_2162 0.890616769  CNVR_1755 0.780401  CNVR_1188 0.877086 
CNVR_1582 0.89197037  CNVR_0875 0.782646  CNVR_1755 0.879525 
CNVR_1058 0.895158089  CNVR_0219 0.786218  CNVR_1582 0.88025 
CNVR_1277 0.898560431  CNVR_1971 0.786325  CNVR_0905 0.882863 
CNVR_1121 0.901750773  CNVR_2162 0.792207  CNVR_0245 0.887725 
CNVR_1974 0.902722661  CNVR_0149 0.795654  CNVR_1458 0.888601 
CNVR_1164 0.904176134  CNVR_0531 0.79588  CNVR_1343 0.890231 
CNVR_1577 0.905743642  CNVR_2014 0.797264  CNVR_1030 0.891142 
CNVR_1707 0.912748429  CNVR_0269 0.798881  CNVR_0010 0.891325 
CNVR_1533 0.914088698  CNVR_1568 0.806497  CNVR_1295 0.894691 
CNVR_0616 0.91507572  CNVR_1318 0.807135  CNVR_0558 0.89571 
CNVR_1130 0.915570464  CNVR_1203 0.807294  CNVR_0548 0.89627 
CNVR_1343 0.91889468  CNVR_2245 0.815749  CNVR_1047 0.896635 
CNVR_1624 0.92098975  CNVR_1656 0.819317  CNVR_0094 0.897196 
CNVR_1592 0.922903057  CNVR_0911 0.822117  CNVR_0462 0.898941 
CNVR_1119 0.923487632  CNVR_1198 0.829083  CNVR_1077 0.899951 
CNVR_1677 0.925367677  CNVR_1013 0.834603  CNVR_0493 0.900721 
CNVR_1318 0.926214361  CNVR_1891 0.83474  CNVR_1820 0.903388 
CNVR_2143 0.930035109  CNVR_1313 0.83723  CNVR_0816 0.906345 
CNVR_2124 0.93267596  CNVR_1662 0.839253  CNVR_1318 0.906884 
CNVR_1755 0.935653015  CNVR_0548 0.840829  CNVR_1088 0.910758 
CNVR_0531 0.936740524  CNVR_2145 0.849247  CNVR_1156 0.911315 
CNVR_0320 0.937689089  CNVR_0145 0.851465  CNVR_1532 0.913872 
CNVR_0118 0.941545369  CNVR_1272 0.862941  CNVR_0403 0.914938 
CNVR_0639 0.942104203  CNVR_0403 0.865392  CNVR_0125 0.914961 
CNVR_0940 0.942352407  CNVR_0217 0.867917  CNVR_1677 0.917861 
CNVR_0919 0.94323468  CNVR_1592 0.869862  CNVR_0063 0.919702 
CNVR_0470 0.94462729  CNVR_1130 0.870269  CNVR_0708 0.921044 
CNVR_1783 0.945148182  CNVR_1670 0.880986  CNVR_2014 0.927443 
CNVR_1859 0.945514313  CNVR_1636 0.882907  CNVR_1502 0.928301 
CNVR_1935 0.946367731  CNVR_0075 0.884186  CNVR_0034 0.931084 
CNVR_0251 0.954313117  CNVR_1395 0.888799  CNVR_1921 0.931488 
CNVR_1730 0.957559954  CNVR_0322 0.901778  CNVR_0295 0.93195 
CNVR_1395 0.957874013  CNVR_2024 0.904088  CNVR_0056 0.933616 
CNVR_2030 0.958773916  CNVR_0216 0.905012  CNVR_1246 0.937479 
CNVR_2047 0.962693856  CNVR_1307 0.907577  CNVR_1090 0.93878 
CNVR_0403 0.964459952  CNVR_0689 0.914138  CNVR_0885 0.941457 
 100 
 
Supp. Tbl. 2.1. Continued        
CNVR_1652 0.966142639  CNVR_0019 0.919754  CNVR_0096 0.943959 
CNVR_1983 0.971724513  CNVR_1108 0.923862  CNVR_1700 0.945451 
CNVR_1308 0.971962883  CNVR_2047 0.923913  CNVR_1370 0.947664 
CNVR_0610 0.972868084  CNVR_0761 0.925139  CNVR_0956 0.948274 
CNVR_0189 0.97309586  CNVR_1187 0.927993  CNVR_1138 0.949686 
CNVR_0052 0.973380333  CNVR_1513 0.950928  CNVR_0084 0.949711 
CNVR_0571 0.974735735  CNVR_1268 0.953117  CNVR_1599 0.953029 
CNVR_1494 0.975649412  CNVR_2200 0.955177  CNVR_1829 0.958263 
CNVR_0498 0.976654834  CNVR_2103 0.955489  CNVR_0949 0.961667 
CNVR_0502 0.981937262  CNVR_1677 0.956386  CNVR_1355 0.962281 
CNVR_1836 0.982250513  CNVR_1821 0.957628  CNVR_1214 0.962606 
CNVR_0895 0.983803453  CNVR_1555 0.957847  CNVR_1315 0.965 
CNVR_2202 0.984125236  CNVR_0018 0.959122  CNVR_0512 0.9664 
CNVR_1914 0.986553435  CNVR_0137 0.961777  CNVR_1233 0.967656 
CNVR_1614 0.989448322  CNVR_1841 0.968581  CNVR_2162 0.970014 
CNVR_0785 0.991500657  CNVR_0570 0.971577  CNVR_1148 0.973925 
CNVR_0224 0.992043783  CNVR_0247 0.971895  CNVR_0128 0.978455 
CNVR_1656 0.994289114  CNVR_0184 0.976977  CNVR_1990 0.987382 
CNVR_1444 0.994409653  CNVR_2148 0.985161  CNVR_1900 0.987913 
CNVR_0261 0.995094473  CNVR_1826 0.99405  CNVR_1788 0.990494 
CNVR_1167 0.998420039  CNVR_1956 0.996512  CNVR_1185 0.992993 
CNVR_1854 0.999899578  CNVR_0165 0.998806  CNVR_1988 0.998016 
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Supplementary Table 2.2. Joint analysis of TRPM2 SNP UKUL3936 (Comparison 1).   
Results of joint analysis comparing clinical foals with the combined subclinical and 
unaffected foals (comparison 1). 
 
Genotype  
Standard Model Clinical foals Subclinical + 
Unaffected foals 
P value Odds Ratio (95% 
CI) 
AA 72% (31/43) 43% (89/205) NA 1 (NA) 
AB 23% (10/43) 46% (95/205) 0.0016 0.29 (0.11 to 0.62) 
BB   5% (2/43) 11% (21/205) 0.0826 0.27 (0.06 to 1.18) 
 
Dominant Model  
Not AA 28% (12/43) 57% (116/205)  NA 1 (NA) 
AA 72% (31/43) 43% ( 89/205) 0.0007 3.50 (1.71 to 7.16) 
 
Additive Model  
f(A)* 2(0 to 2) 1(0 to 2) 0.0019 2.71 (1.45 to 5.06) 
 84% (72/86) 66% (271/410)   
* Median (range) reported for frequency of allele A, along with the proportion of A alleles 
among all alleles represented for each group.  Joint analysis includes genotypes derived from 
SNP array and PCR genotyping. 
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APPENDIX 2.3 
 
Supplementary Table 2.3. Joint analysis of TRPM2 SNP UKUL3936 (Comparison 3).  
Results of the joint analysis comparing clinical foals with unaffected foals. 
 
Genotype  
Standard Model Clinical foals Unaffected foals P value Odds Ratio (95% 
CI) 
AA 72% (31/43) 47% (23/49) NA 1 (NA) 
AB 23% (10/43) 47% (23/49) 0.0177 0.32 (0.13 to 0.81) 
BB   5% (2/43) 6% ( 3/49) 0.4622 0.49 (0.08 to 3.20) 
 
Dominant Model  
Not AA 28% (12/43) 47% (23/49) NA 1 (NA) 
AA 72% (31/43) 53% (26/49) 0.0179 2.92 (1.22 to 6.98) 
 
Additive Model  
f(A)* 2(0 to 2) 1(0 to 2) 0.0398 2.20 (1.05 to 4.64) 
 84% (72/86) 70% (69/98)   
* Median (range) reported for frequency of allele A, along with the proportion of A alleles 
among all alleles represented for each group.  Joint analysis includes genotypes derived from 
SNP array and PCR genotyping. 
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APPENDIX 2.4 
 
Supplementary Figure 2.1. Quantile-quantile (QQ) plots of expected chi-squared 
significance values plotted against the observed values. QQ plots for (A) comparison 1, 
(B) comparison 2, (C) comparison 3, and (D) mixed-effects model. 
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APPENDIX 3.1 
 
 
Supplementary Figure 3.1. Gene expression, clinical phenotype, and genotype 
relationship.     
 
 
 
 
 
 
 
 
